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BACKGROUND:  Cystic fibrosis (CF) patients grow poorly and tend to be 
malnourished.  They frequently suffer from lung infections necessitating the repeated use 
of antibiotics.   
AIM:  This study was conducted to determine whether supplementation with a probiotic 
Lactobacillus reuteri (L. reuteri) could reduce the incidence and duration of lung 
infections, and whether this would impact on their anthropometric data.  The secondary 
purpose was to compare the nutritional status of the CF patients attending CF clinics in 
Kwazulu-Natal (KZN) with CF patients attending CF clinics in Cape Town (CT). 
METHODS:  Twenty three CF patients 6-31 years of age from 2 CF clinics in Kwazulu-
Natal started the study although only 16 patients completed it.  The study was a 
randomized, double blind, placebo controlled crossover trial with six months on placebo 
and six months on probiotic.  Weight, height, mid arm circumference (MAC), triceps skin 
fold thickness (TSF), forced expiratory volume in 1 second (FEV1) and forced vital 
capacity (FVC) were measured, sputum collected and a symptom diary completed over 
the 12 month period.  Anthropometric data of CF patients attending CF clinics in CT was 
obtained from the publication by Westwood & Saitowitz (1999). 
RESULTS:  Compliance with taking the L. reuteri was poor.  Most took only 50% of the 
required daily dose.  Probiotic supplementation showed a slight (non significant) trend to 
improve FEV1 and FVC, while no significant difference could be seen in the number and 
duration of the lung infections.  Sputum analysis showed a non significant trend towards 
the probiotic reducing the number of bacteria in the sputum.  There was a significant 
reduction of symptoms for fever, running nose, sore throat and ear ache while on placebo.  
There was a significant increase in weight gained off probiotic compared to the probiotic 
period. The changes in height, weight for age (WFA) percentiles, height for age (HFA) 
percentiles, WFA and HFA Z-scores, percentage expected weight for age and percentage 
expected height for age all showed no difference whether on or off probiotic.  Over half 
the CF children in the KZN clinics were underweight for their actual height compared to 
one third in the CT clinics with a higher number of subjects below the 5th percentile for 
MAC and TSF readings compared to CT. 
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CONCLUSION:  Due to a small sample size and poor compliance no firm conclusions 
could be drawn.  However a slight (non significant) improvement could be seen in favour 
of the probiotic for FEV1, FVC, and sputum analysis.  Although all other findings were 
not significantly different it would be of benefit to carry out further investigation with 
improved compliance with the probiotic to see if the parameters set out above could be 
improved.  The KZN and CT CF groups were comparable and the nutritional status of CF 
patients on KZN was well below that of the CT CF clinics and further monitoring would 
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CHAPTER 1:  INTRODUCTION, THE PROBLEM AND ITS SETTING 
 
1.1 IMPORTANCE OF THE STUDY 
 
Cystic fibrosis (CF) was first identified by Andersen 1938 who published a paper 
describing the characteristics of the disease (Wikipedia citing Andersen 1938).  Although 
in some countries such as Asia the existence of CF is not well recognized (Wikipedia 
2006), the prevalence in first world countries is reasonably well established (World 
Health Organization WHO 2007).  In 2000 the CF registry of the United States of 
America (USA) had approximately 22303 patients registered (Zhang & Lai 2004).  In 
Britain currently there are 7500 registered CF patients and it is considered the most 
common life threatening inherited disease in the United Kingdom (UK) and Europe (UK 
CF association 2007, CF association Ireland 2007, European CF association 2007).  
Thirty thousand patients are currently registered in Europe (European CF association 
2007).  It is more common in those from European descent with the Jewish population 
being the most effected (Wikipedia citing Kerem, Chiba-Falek & Kerem 1997).  In a 
similar situation to Asia, the prevalence of CF in South Africa (SA) is thought to be 
under diagnosed particularly in the non caucasian population (South African Cystic 
Fibrosis Consensus Document 2007).  In SA CF is thought to effect 1 in 27 caucasians, 1 
in 50 coloureds and 1 in 90 blacks (South African Cystic Fibrosis Consensus Document 
2007).   
 
At the time of Andersen’s publication (1938) CF patients were often misdiagnosed as 
suffering from kwashiorkor.  This highlights the well recognised association between 
malnutrition and CF (Pencharz & Durie 2000).  In those early days, failure to thrive in 
infancy was common and their maximum life span was 10 to 15 years (Elbourn & Bell 
1996).  In more recent years the vastly improved medical and nutritional therapy has 
resulted in a significant decrease in the incidence of malnutrition and consequently CF’s 
survive on average 37 years, with some reaching their late forties (BUPA 2006).  
Malnutrition however still appears to be a significant problem among the CF population. 
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Anthropometric data supplied by the different CF registries (America, Canada, United 
Kingdom and Europe) has been difficult to compare as different countries have reported 
the prevalence of malnutrition using different growth standards.  In the USA in spite of 
improved therapy, CF children still experienced subnormal growth at all ages (Lai, 
Corey, Fitzsimmons, Kosorok & Farrell 1999) and malnutrition was particularly 
pronounced in infants, adolescents and patients with newly diagnosed CF (Lai, Kosorok, 
Sondel, Chen, FitzSimmons, Green, Shen, Walker & Farrell 1998).  According to Shaw 
& Lawson (2007, p 179) malnutrition amongst the UK CF patients is still a significant 
issue as in Spain where approximately one fifth suffer from malnutrition (Molina, 
Bozano, Oses & Allue, 2001).  In SA, anthropometric data on CF patients is limited as 
the only published information is from the Cape Town cystic fibrosis clinic (Westwood 
& Ireland 2000).  In their study Westwood & Ireland (2000) showed that malnutrition, 
especially growth failure, is also a significant problem in CF patients in Cape Town.   
 
Malnutrition increases susceptibility to infections (Shaw & Lawson 2007, p179) which is 
particularly detrimental in CF patients as lung infections are the major cause of death 
(Anthony, Paxton, Catto-Smith & Phelan 1999; Chandra 1997; Calder & Kew 2002). 
 
Pseudomonas aeruginosa is one of the most important pathogens in lung infections in CF 
patients and has the greatest impact on their life expectancy (Hart & Winstanley 2002).  
The treatment options are extremely limited as very few antibiotics are effective against 
P. aeruginosa and the development of resistance is a very real issue.  In SA 
approximately two thirds of the patients attending Groote Schuur Hospital (Cape Town) 
CF clinic were colonized with P. aeruginosa and of those one third were resistant to the 
antibiotic fluoroquinolone (Ventre, Wilcox & Roditt 2000).  In light of the limited 
treatment options, other strategies to enhance the CF patient’s resistance to infection are 
crucial.   
 
Supplementation with probiotics has been shown to stimulate the systemic immune 
system (Bourlioux, Koletzko, Guarner & Braesco 2003).  In healthy children with a 
normal population of colonic microflora, supplementation with probiotics has been 
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shown to reduce the incidence of respiratory tract infections (Hatakka, Savilahti, Ponka, 
Meurman, Poussa, Nase, Saxelin & Korpela 2001).  This effect could be more 
pronounced in CF patients as they probably have an abnormal population of colonic 
microflora as a consequence of the frequent use of antibiotics, as well as the unusual 
substrates entering the colon due to food malabsorption (Walters & Littlewood 1998).  A 
disturbance in both the population type and number of the colonic bacteria could suppress 
the immune response.  There are several criteria for the use of a probiotic that will be    
discussed in the literature review.  A single probiotic needed to be used and Lactobacillus 
reuteri was chosen because it is of human origin, is acid and bile stable, colonizes the 
human gastro intestinal tract (GIT), adheres to human intestinal cells, produces 
antimicrobial substances, is antagonistic to pathogenic bacteria, has clinically validated 
and documented health effects, is safe and has a guaranteed viable shelf life and as it 
meets all the criteria of a successful probiotic making it a suitable choice for the trial.  L. 
reuteri, has the potential to stimulate the immune system, possibly reducing the incidence 
and shortening the duration of lung infections while maintaining or preventing 
deterioration in lung function.  A reduction in the number of lung infections would 
decrease both the nutritional requirements and nutrient losses of patients with CF while 
increasing food intake.  This would improve nutritional status, which would enhance 
resistance to lung infections in turn interrupting the malnutrition/infection cycle and 
reducing mortality. 
 
1.2 PURPOSE OF THE STUDY 
 
The primary purpose of the study was to determine whether supplementation with a 
probiotic (L. reuteri) would improve anthropometric measurements, reduce the incidence 
and shorten the duration of lung infections and would maintain or prevent deterioration in 
lung function in CF patients attending the CF KwaZulu-Natal (KZN) clinics in Durban.  
The secondary purpose of the study was to compare the nutritional status at the end of the 
study of CF patients attending CF KZN clinics in Durban with CF patients attending CF 
clinics in Cape Town from the published data by Westwood & Saitowitz (1999). 
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1.3 STUDY DESIGN 
 
This was a randomized, double blind, placebo controlled crossover trial run over the 
period of a year.    
 
Figure 1 is included in order to clarify the study design. This figure is repeated in Chapter 
3 alongside the objectives indicating exactly the timing and the measurements taken for 
each objective. 
 
1.4 OBJECTIVES AND HYPOTHESES 
 
1.4.1    Weight 
 
1.4.1 1  To determine weight at baseline1, start of the probiotic and end of 
probiotic for the group as a whole as well as by age and gender and to compare weight 
gained over the six months prior to and while taking the probiotic.   
 
The hypothesis was that all subjects’ weights would improve more while taking the 




1.4.2.1  To determine height at baseline, start of the probiotic and end of probiotic 
for the group as a whole as well as by age and gender and to compare height gained over 
the six months prior to and while taking the probiotic. 
 
The hypothesis was that all subjects 20 years and younger would improve in height more 
while taking the probiotic.  
 
                                                 
1 Baseline was six months before the start of the probiotic 
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1.4.3 Comparison of anthropometric status of cystic fibrosis patients in Durban and 
Cape  Town 
 
1.4.3.1  To compare the percentage expected weight for height (%EWFH), mid 
arm circumference (MAC) and triceps skinfold thickness (TSF) in CF patients in Durban 
and Cape Town.  For the comparison to the Cape Town patients this data was obtained 
from the publication by Westwood & Saitowitz (1999).   
 
1.4.4 Incidence and duration of lung infections 
 
1.4.4.1   To determine and compare the incidence and duration of lung infections 
while taking the probiotic and while taking the placebo.  
 
The hypothesis was that supplementation with L. reuteri would reduce both the incidence 
and duration of lung infections in CF patients. 
 
1.4.5  Lung function  
 
1.4.5.1  To determine and compare the mean change in lung function while taking 
the probiotic and while taking the placebo. 
 
The hypothesis was that CF patients while taking L. reuteri would experience an 
improvement in lung function. 
 
1.4.6  Sputum analysis 
 




1.4.6.2   To determine and compare the change in the presence and quantity of P. 
aeruginosa (dry and mucoid), S. aurens and B. cepacia in the sputum while on the 
probiotic and while on the placebo.  
 
The hypothesis was that CF patients while taking L. reuteri would experience a decrease 
in the count of P. aeruginosa (dry and mucoid), S. aurens and B. cepacia in the sputum. 
 
1.4.7  Symptoms 
 
1.4.7.1  To determine and compare the number of episodes of symptoms 
(coughing, wheezing, thrush, diarrhea, constipation, vomiting, stomach ache, fever, runny 
nose, sore throat and ear ache) while on the probiotic and of the probiotic. 
 
The hypothesis was that CF patients while taking L. reuteri would experience a decrease 
in the number of episodes of symptoms. 
 
1.4.8   Food frequency questionnaire regarding pre and probiotic use 
 
A food frequency questionnaire was used to determine the frequency of use of pre and 
probiotics.  
 
1.5  STUDY PARAMETERS 
 
The study included all CF patients, 6 years and older, who attended either the Private CF 
clinic at St Augustine’s hospital or the State CF clinic at Addington hospital both in 
Durban, KZN and who had attended either clinic for longer than one year.  Those who 
had regularly been supplementing with L. reuteri and/or other probiotics and/or prebiotics 
or patients with a Shwachman score2 of less than 40 were excluded from the study.  For 
                                                 
2 The Shwachman score was used to measure the severity of lung disease.  The questionnaire consists of 
four sections, each with a rating from 0-25.  The four sections included are general activity, physical 
examination, nutrition and chest x-ray.  A score of 86-100 is excellent, 71-85 is good, 56-70 is mild, 41 -55 
is moderate and 0-40 indicates severe lung disease.   
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the comparison of Durban patients to the Cape Town patients, the Cape Town data was 
obtained from the publication by Westwood & Saitowitz (1999).   
 
1.6 DEFINITION OF TERMS 
 
Age groups 
The age groups were divided into 6 to 9.99 year olds, the 10 years to 12.99 year olds, the 
13 to 19.99 year olds and the ≥20 year olds.  Non adolescents were defined as being ≤ 
12.99 years, the adolescents as between 13 to 19.99 years old and the adult as ≥ 20 years 
old.  As the study ran for a 12 month period two subjects started in the ≤ 19.99 year old 
group but moved into the ≥ 20 year old group during this time frame.   
 
Anthropometric measurements 
For the purpose of this study anthropometric measurements refers to the measurements of 
body size and composition, including height, weight, body circumference measurements 
(mid arm circumference) and skinfold thickness (triceps skinfold thickness) that was 
collected in this study.   
 
Baseline  
Baseline referred to the first set of measurements that was taken six months prior to 
starting the probiotic.  Patients were divided into two groups.  Group A that started the 
probiotic first these measurements were taken from the patient’s medical record.  This 
was six months before the trial started.  For group B, the group that started the placebo 
first, these measurements were taken at the start of the study (that is start of placebo) as 
this was six months before the start of the probiotic.  
 
Cystic fibrosis  
Patients were included in the study if their diagnosis had been made on the basis of two 
positive sweat tests where the sweat chloride exceeded 60 mmol/l in children and 70 
mmol/l in adults and/or the presence of CF mutations had been established by DNA 
testing. 
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Duration of lung infections 
The duration was measured as the number of days of prescribed antibiotic treatment 
required to treat the lung infection as ordered by the doctor.   
 
Incidence of lung infections 
The incidence was the number of new lung infections experienced over the 12 month 
study period for which the doctor wrote up antibiotic treatment.  Continuous antibiotic 
treatment was not included as a new infection.  The 12 month study period included both 
placebo and probiotic treatment for both groups.   
 
Lung function 
Lung function was measured by the forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC).  FEV1 was defined as the maximal amount of air that can be 
exhaled in one second after taking a deep breath.  FVC was defined as the total amount of 
air that can be exhaled until no more air can be exhaled.  
 
Microbiological culture 
Microbiological culture is a method of growing microbial organisms to determine what 
type and the number present in a sputum sample being tested.   
 
Nutritional Status  
For the purpose of this study height for age, weight for age, weight for height, %EWFH, 
MAC and TSF percentiles were used to establish the nutritional status of the CF patients 
in the Durban clinics.  This was done to compare to the Cape Town CF clinic. 
 
Prebiotic 




Is a beneficial bacteria that has health properties in that it protects the host and prevents 
disease.  
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Probiotic used in this study   
Biopro’s Lactobacillus reuteri  straws were used.  Each straw contained a guaranteed 
dose of 1 x 108 colony forming units (cfu).  The straws were to be used to drink 100 ml to 
250 ml of any liquid, which was at room temperature or cold once a day (for example 
water or juice). 
 
Placebo used in this study 
Biopro provided a straw which was similar to the product but which did not contain L. 
reuteri. 
 
Severity of Lung Disease (Shwachman score) 
The Shwachman score was used to measure the severity of lung disease.  The 
questionnaire consists of four sections, each with a rating from 0-25.  The four sections 
included are general activity, physical examination, nutrition and chest x-ray.  A score of 
86-100 is excellent, 71-85 is good, 56-70 is mild, 41 -55 is moderate and 0-40 indicates 
severe lung disease.  Patients scoring less than 40 out of 100 were excluded from the trial. 
 
1.7  ABBREVIATIONS 
 













Table 1  Abbreviations  
Abbreviation Meaning 
ANOVA Analysis of variance 
B. cepacia Burkholderia cepacia 
BMI Body mass index 
CDC Center for Disease Control  
CF Cystic Fibrosis 
Cfu Colony forming units  
CHO Carbohydrate  
CT Cape Town 
ED Eating disorders 
FEV1 Forced expiratory volume in one second 
FVC Forced vital capacity 
GI Gastrointestinal 
GIT Gastro intestinal tract 
H. influenzae Haemophilus influenzae 
HFA Height for age 
IQR Inter quartile range 
KZN KwaZulu-Natal 
L. acidophilus Lactobacillus acidophilus 
L. casei Lactobacillus  casei 
L. reuteri Lactobacillus reuteri 
LGG Lactobacillus rhamnosus Gorbach and Goldin  
MAC Mid arm circumference 
NE   Neutrophil elastase    
P. aeruginosa Pseudomonas aeruginosa 
PPB Potentially pathogenic bacteria  
S. aureus Staphylococcus aureus 
S. boulardii Saccharomyces boulardii 
SA South Africa 
TSF Triceps skinfold thickness 
WFA Weight for age  
%EHFA Percentage expected height for age 
%EWFA Percentage expected weight for age 
%EWFH Percentage expected weight for height 
UK United Kingdom 
USA United States of America 







1.8   ASSUMPTIONS 
 
1.8.1 That the local sweat tests and genetic testing was accurate and that patients 
attending the CF clinic actually have CF. 
 
1.8.2 That the sputum tests were both accurate and reproducible and that patients could 
produce sputum. 
 
1.8.3 The L. reuteri straws did contain the dose stated by the manufacturer of 1 x 108 
viable cfu. 
 
1.8.4 That the presence of lung infections was detectable – making the assumption that 
the length of antibiotic prescribed reflected the severity of the infection. 
 
1.8.5 That the participants were compliant with enzyme therapy, daily physiotherapy, 
nebulisation, reporting infections in time and taking their antibiotics as prescribed. 
 
1.8.6 That the CF patients would be interested in testing a new treatment and that they 
would be compliant with taking the L. reuteri straws or placebo as instructed and 
would record and report information in the symptom diary accurately. 
 
1.8.7 That the CF patients would return the unused straws after use and not just open 










1.9   SUMMARY 
 
Both malnutrition and antibiotic resistance are significant concerns in the CF population 
in SA.  If supplementation with L. reuteri could be shown to stimulate the immune 
system, possibly reducing the incidence and shortening the duration of lung infections 
while maintaining or preventing deterioration in lung function then a reduction in the 
number of lung infections would decrease both nutritional requirements and nutrient 
losses of the patients with CF while increasing food intake.  This would improve 
nutritional status, which would enhance resistance to lung infections in turn interrupting 
the malnutrition/infection cycle and reducing mortality.  Data is scarce concerning the 
prevalence of malnutrition in local CF patients in KZN. It is important to ascertain the 
prevalence of malnutrition locally as well as to determine if supplementation with a 
probiotic can influence the incidence and duration of lung infections and if so whether 
this impacts on their anthropometric data.    
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CHAPTER 2:  REVIEW OF RELATED LITERATURE 
 
2.1 INTRODUCTION 
Cystic fibrosis was identified as early as 1938.  As the condition was not well described 
in the literature, these patients were mistakenly identified as suffering from kwashiorkor 
demonstrating the close association between malnutrition and CF.  Since 1938, improved 
care has resulted in a significant decrease in the prevalence of malnutrition in CF patients 
although approximately one fifth still present with frank malnutrition (Molina et al 2001).  
Malnutrition is particularly detrimental to the CF patient as this predisposes them to 
infections and recurrent lung infections are the major cause of death in the CF patient 
(Anthony et al 1999; Chandra 1997; Calder & Kew 2002).   
The prevention and treatment of lung infections in CF patients is particularly challenging 
as P. aeruginosa, the most problematic pathogen responds to a limited number of 
antibiotics (Bengmark 1998).  In a SA study by Ventre et al (2000) they demonstrated 
that one third of there CF population were resistant to an antibiotic which is used to treat 
CF patients.  The issue of resistance is especially important as the treatment regime in CF 
patients is demanding and non-compliance to therapy in any chronic disease is well 
described (Dodd & Webb 2000).  The reliance on these antibiotics might be reduced by 
the use of probiotics.  These non-pathogenic bacteria have been shown to stimulate the 
systemic immune response and there is some evidence showing that they may reduce the 
incidence and duration of respiratory tract infections in healthy children (Hatakka et al 
2001).    
This review of the literature will consider the prevalence of CF in South Africa, the 
prevalence of malnutrition in CF patients in SA, whether compliance is an issue in the 
treatment of CF patients, whether probiotics could reduce the incidence of lung infections 




2.2 PREVALENCE OF CYSTIC FIBROSIS 
Although a CF data base is being developed in SA, the current statistics on the prevalence 
are imprecise.  It is thought that there are approximately 600 people suffering from CF in 
SA - of these 42 are known to reside in Kwazulu-Natal and most attend either of the two 
CF clinics.   
 
The CF clinic in Cape Town, situated at the Red Cross War Memorial Children’s 
Hospital, has published the only studies on the incidence of malnutrition in CF patients in 
SA.   
 
2.3 PREVALENCE OF MALNUTRITION IN CYSTIC FIBROSIS PATIENTS IN 
SOUTH AFRICA 
 
A study done by Hill, MacDonald, Bowie & Ireland (1988) reported that 36% of the CF 
population of the Red Cross Hospital were below the 3rd percentile for weight and 24% 
were below the 3rd percentile for height (Hill et al 1988) indicating that a significant 
percent suffered from severe malnutrition.   
 
Westwood & Saitowitz (1999) reassessed the nutritional status of the CF population at 
the Red Cross Hospital in 1996.  Their study on 45 patients included the entire population 
of this CF clinic minus those under 2 years old, those with very severe lung disease and 
those who lived more than 60 km away.  As 7 did not complete the 3 day weighed food 
record (18.4%), a final total of 38 patients were included.  They assessed malnutrition 
using weight for height (WFH), TSF and MAC.  No comment was made on the number 
remaining below the 3rd percentile for weight.  When looking at the weight for height a 
total of 13.5% were moderately or severely malnourished (Table 2).  An interesting 
occurrence is the prevalence of overweight.  Westwood & Saitowitz (1999) did not 
comment of this.  As 16.2% were below the 5th percentile for height this is also an 
improvement on the 1988 figures where 24% were below the 3rd percentile.  These 
authors found the mean height was 96% of expected.  They found that 38.1% and 28.6% 
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were below the 5th percentile for TSF and MAC respectively.  These results could have 
been skewed by the exclusion of those with serious lung disease however.   
 
Table 2  Anthropometric indices of cystic fibrosis at the Red Cross Hospital in 1996 
(Westwood & Saitowitz 1999) 
Frequency (%) 
WFH > 110% (overweight) 5.4 
WFH 90-110% (normal) 62.2 
WFH 85-89% (underweight) 5.4 
WFH 80-84% (mild malnutrition) 13.5 
WFH 75-79% (moderate malnutrition) 5.4 
WFH < 75% (severe malnutrition) 8.1 
HFA < 5th percentile (n=21) 16.2 
MAC < 5th percentile (n=21) 38.1 
TSF < 5th percentile (n=21) 28.6 
WFH = weight for height, HFA = height for age, MAC = mid-arm 
circumference, TSF = triceps skinfold thickness  
 
Westwood & Saitowitz (1999) found that the prevalence of malnutrition was related to 
age.  In the above 10 years old group 47% were malnourished versus 14.3% in the 10 
years and under group.  This seemed to coincide with the decrease in compliance often 
seen in adolescents. They concluded that young SA children with CF are growing 
adequately but more attention needs to be paid to the older children and adults. 
 
Westwood & Ireland (2000) in a later publication compared the growth of CF patients 
who were regularly attending the clinic at the Red Cross Hospital for the first 6 months of 
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1986 (Group 1, n = 49) compared to the first 6 months of 1996 (Group 2, n = 63).  The 
study methodology was similar to their previous study.  Their results showed no 
difference in weight for age (WFA) between the 2 groups.  Insufficient height 
measurements were available from Group 1 so no conclusions could be drawn for height 
for age and weight for height.  They concluded that there was a significant improvement 
in growth from 1986 as indicated by a 14.3% improvement in WFA in 5 to 10 year old 
children (10th to just below the 50th percentile).   
 
Westwood & Ireland (2000) commented that in spite of the reductions in health services 
and support in SA for those with uncommon diseases requiring specialized health care, 
the nutritional status of CF patients seemed to be improving.  They attributed the 
improvement to the development of improved enzymes in combination with the high 
energy, high fat diet, the early use of nutritional supplementation plus regular meetings 
with the whole health team to encourage compliance (Westwood & Ireland 2000, 
Westwood & Saitowitz 1999).  Westwood & Ireland (2000) concluded that although 
there appears to have been an improvement in the prevalence, malnutrition especially 
growth failure, is still a significant problem in the over 10 year olds which is probably 
due to the progression of lung disease and a decreased compliance associated with 
adolescence.   
 
2.4 COMPLIANCE IN CYSTIC FIBROSIS PATIENTS 
 
Compliance of CF patients internationally, includes eating adequately to maintain growth 
and weight, taking enzymes and drugs, daily physiotherapy as well as regular visits to the 
CF clinic (Pendleton & David 2000).  Clinic visits occur either once a month or every 2, 
3 or 6 months.  It has been demonstrated however that CF patients that attend CF clinics 
regularly have higher growth patterns and improved respiratory function (Anthony et al 
1999).  Clearly the treatment regime is very time consuming requiring a high degree of 
compliance. 
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2.4.1 Measurement of compliance 
 
Adherence to clinic visits is easy to establish but compliance in other areas such as food 
and medication is more difficult to ascertain.   
 
Compliance can be measured either subjectively or objectively (Dodd & Webb 2000).  
Subjective measures include questionnaires, symptom diaries or chart type observation.  
Objective measures include both direct measures as in lung function readings, heights 
and weights and indirect measures of counts of antibiotics and enzymes remaining after 
treatment.   
 
Dodd & Webb (2000) commented that most studies on compliance in CF rely on patients 
using a subjective self reporting type questionnaire which usually overestimate 
compliance when compared to objective tests.  Often there is a huge difference between 
the patient’s and the medical team’s perception of compliance (Pendleton & David 2000).  
Patients and families who lack the skills and confidence to implement treatments may tell 
the medical team what they think they want to hear rather than what they are actually 
doing as they may be afraid of being reprimanded (Anthony et al 1999). 
 
2.4.2 Compliance in children 
 
CF patients comprise of infants through to adults.  The treatment adherence of the infant 
and child 10 years old and under largely depends on the commitment of their primary 
care givers.  As many adults feel that a low fat intake is healthy, some experience 
difficulty in believing that a high fat intake is actually appropriate for a CF child.  
Powers, Patton, Byars, Mitchell, Jelalian, Mulvihill, Hovell & Stark (2002) showed that 
CF infants and toddlers only took in 34% of energy from fat and not the 40% as 
recommended.  In addition he went on to say that these age groups (n=35) were not 
meeting the CF energy recommendation of 120% of the RDA.  In the SA studies by 
(Westwood & Saitowitz 1999; Westwood & Ireland 2000) compliance seemed better in 
the younger children.  
 20
2.4.3 Compliance in adolescents 
 
Adolescence was found to be the worst period of compliance (Anthony et al 1999) as 
indicated by the increasing malnutrition in CF patients over 10 years old.  Teenagers with 
CF face the same psychosocial problems as their healthy counterparts.  Of particular 
concern is the preoccupation with figure shape, body weight, dieting and “healthy eating” 
prevalent amongst teenagers, particularly females.  The CF patient’s high fat diet is the 
opposite of the current health message promoting a reduction in the intake of fat to 
attempt to maintain health.  This could make them feel isolated and “not trendy or cool”.  
Eating disorders (ED), which are a high risk in this age group, may be an additional 
challenge as disease treatments which focus on control and food are suspected to 
predispose to ED (Stark, Mulvihill, Jelalian, Bowen, Powers, Tao, Creveling, Passero, 
Harwood, Light, Lapey & Hovell 1997).   
 
2.4.4 Compliance in adults 
 
Due to the improved health care CF patients are living longer. This means that the older 
CF patients are studying, securing full time employment, marrying and starting families.  
All this requires time allowing less time for compliance to the CF patients daily treatment 
requirements (Dodd & Webb 2000).  The longest living CF patient in the KZN clinic is 
currently in her late forties.  Usually the older the CF patient the more the infections, 
which means more treatment time, more time off work and less time with their family 
and to relax.  Not many studies have addressed the issue of compliance in CF adults.  It is 
interesting to note that male CF patients will have a 5 year survival advantage to females 
(Anthony et al 1999) and male CF generally do better than there female counterparts.  
The reason for this has not yet been established but it is thought that the poorer nutritional 






2.4.5 Reasons for non-compliance 
 
Three basic causes of non-compliance in CF patients have been identified as inadequate 
knowledge, psychosocial resistance and educated non-compliance (Koocher, McGrath & 
Gudas 1990).  Abbott & Gee (1998) grouped reasons for non-compliance in CF patients 
slightly differently into 4 categories which included health, time, social and emotional 
reasons.  They found that health and time were the major reasons for non-compliance 
(Table 3).   
 
Table 3  Reasons for non-compliance (Abbott & Gee 1998) 
Category Reasons given 
Health ‘I feel well without treatment’  
‘I’m not as serious as others’  
‘I don’t feel any benefit’  
Time ‘not enough time’  
‘I am too busy’  
‘I forget’ 
Social ‘interferes with my social life’  
‘embarrassing taking enzymes in 
public or doing physiotherapy’  
Emotional ‘I resent it’  
‘I can’t be bothered’  
 
Dodd & Webb (2000) claim that in addition in CF the actual treatment determines 
compliance.  They found that where treatments offered an immediate benefit there was 
84% compliance whereas with treatments that offered a long term but no immediate 
benefit the compliance dropped to between 41 to 65%.  For example, there was an 80% 
compliance with enzymes, insulin and exercise and only a 50% compliance with chest 




Interestingly regardless of age Gudas, Koocher & Wypij (1991) established that 
optimistic CF patients were more compliant than pessimistic CF patients.  Pendleton & 
David (2000) suggested that this type patient may have found a way of coping with CF 
rather than developing a rebellious attitude towards their medical care.   
 
A lack of compliance in CF patients with regard to an adequate food intake predisposes 
to malnutrition which predisposes to lung infections.  Non-compliance with medication, 
physiotherapy and exercise also predisposes to lung infections.   
 
2.5  PREDISPOSITION TO LUNG INFECTIONS IN CYSTIC FIBROSIS 
 
Because of the mutation of the gene in CF patients, the normal transport of electrolytes 
across epithelial membranes is disturbed causing the mucus in their airways to be thick, 
sulphated and easily able to form aggregates (Bals, Weiner & Wilson 1999).  Bacteria 
that are carried by air into healthy lungs are trapped by the mucus layer and moved 
upwards towards the pharynx by the “mucociliary escalator” as shown in Figure 2 
(Williams 2002).  These are then either swallowed or expectorated.  In spite of the fact 
that the airways above the vocal cords are heavily contaminated with bacteria, the lower 
airways remain sterile because of the action of the “mucociliary escalator” (Hart & 
Winstanley 2002).   
 
 
 Figure 2  Mucocillary escalator (Williams 2002).   
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As the mucus in the CF lungs is much thicker, the bacteria are trapped but cannot be 
transported out of the lower airway resulting in the frequent lung infections.  The most 
problematic pathogen in the CF lungs is P. aeruginosa (dry and mucoid) followed by 
Staphylococcus aureus and Burkholderia cepacia (West, Zeng, Lee, Kosorok, Laxova, 
Rock, Splaingard & Farrell 2002, Hart & Winstanley 2002).  There are few treatment 
options as only a limited number of antibiotics, such as fluoroquinolone, are effective 
against P. aeruginosa.  Resistance to fluoroquinolone was shown in one third of CF 
patients in SA (Ventre et al 2000).   
 
In addition, extracellular fluid cultured from normal airways has been shown to have a 
bacteriocidal effect but this has not been shown for the extracellular fluid from the CF 
lungs (Smith, Travis, Greenberg & Welsh 1996).  The prolonged microbial colonization 
and infection may be exacerbated by a defective non-specific immune system (Hart & 
Winstanley 2002).   
 
Chronic bacterial lung infections in CF patients cause the immune system to respond by 
producing specific antibodies, forming immune complexes, rapidly recruiting neutrophils 
from the blood stream, and producing cytokines.  This is associated with the release of 
lysosomal enzymes particularly neutrophil elastase (NE).  NE interferes with ciliary 
beating, encourages mucus production and further facilitates P. aeruginosa adherence.  
This in turn could result in acquired immune suppression (Memoranda 1994).   
 
An alternative treatment option which could reduce both the reliance on antibiotics and 
stimulate the immune system is an interesting concept.  Bengmark (1998) suggested that 
supplementation with non pathogenic bacteria such as probiotics could stimulate the 
immune system thus reducing or negating the need for antibiotics.  
 
2.5.1 Discovery of probiotics 
 
In the 1900, the Nobel Prize was awarded to Elie Metchnikoff for his hypothesis “that the 
long, healthy lives of Bulgarian peasants were the result of their consumption of 
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fermented dairy products” (Kopp-Hoolihan 2001).  This eventually resulted in the 
hypothesis that micro organisms in the gastro intestinal tract (GIT) could beneficially 
influence health not only in the GIT but in other areas of the body.  In turn this lead to the 
concept of probiotics, the term probiotics being coined from ‘pro-life’ (Reid, Jass, 
Sebulsky & McComick 2003). 
 
2.5.2 Definition of a probiotic 
 
A probiotic is a live micro organism which, when consumed by either animals or humans, 
alters their indigenous microflora resulting in health benefits to the host (Stanton, 
Gardiner, Meehan, Collins, Fitzgerald, Lynch & Ross 2001).    
 
2.5.3 Indigenous microflora  
 
The indigenous intestinal microflora of healthy people consists of a static resident 
population and a transient population.  Both the static and transient bacterial flora plays 
an important role in maintaining health.  Potentially pathogenic bacteria (PPB) such as P. 
aeruginosa and pathogenic bacteria are a natural part of this bacterial flora.  They are 
normally kept in check by the non pathogenic bacteria, the gut-associated lymphoid 
tissue as well as non-specific defence factors (Van der Waaij 1999).  For example 
Lactobacillus, found throughout the human GIT, protects the enterocytes, controls 
metabolic and immunologic processes and prevent pathogens from colonizing (Levy 
2000). 
 
The composition of the diet, especially the carbohydrate (CHO) content, is important to 
maintain the balance of healthy microflora as this provides their nutrients (Walters & 
Littlewood 1998).  As the resident microflora is dictated by the food substrates in the GIT 
as well as the use of medication such as antibiotics, a disturbance in the microflora’s food 
supply and/or the use of antibiotics (Levy 2000) would result in a derangement in the 
normal microflora which in turn would imply a negative impact on health.   
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According to Walters & Littlewood (1998) the faeces of CF patients contain excessive 
amounts of CHO, bile acids, fat and nitrogen in spite of the use of pancreatic enzymes. 
These authors hypothesised that the microflora in the colon were unable to metabolise 
high concentrations of CHO residues resulting in GIT discomfort and an overfilled colon 
which is common CF patients.  They suggested that this resulted in a predominance of 
aerobic organisms which were unable to break down primary bile salts to secondary bile 
salts.  High concentrations of bile acids would preclude the existence of bacteria that 
were not resistant to bile acids further altering the Gastrointestinal (GI) microflora. 
 
Only one study was found that attempted to establish the composition of the “normal” 
microflora in CF patients. This controlled study on 29 CF children investigated their 
faecal microflora (Roy, Delage, Fontaine, Robitaille, Chartrand, Weber & Morin 1979) 
but unfortunately looked at the amounts of anaerobic versus aerobic bacteria rather than 
the presence and quantity of individual species.   
 
In Roy’s study the children were divided into 3 groups consisting of 7 off antibiotics, 10 
on oral Cloxacillin and 6 on intravenous triple therapy composed of Cloxacillin, 
Gentamycin and Carbenicillin.  They ate a moderately low fat diet (50 to 75g per day) 
and all took pancreatic supplementation.  The control group consisted of 7 healthy 
children with no gastrointestinal problems, hepatic or pancreatic disease and who ate a 
normal diet.   
 
A reduction in the total microflora was shown in the CF children off antibiotics and those 
on triple therapy.  CF children on Cloxacillin did not show a reduced microflora.  The 
composition of the microflora was altered in all groups.  Aerobes were increased in CF 
children off antibiotics versus controls.  The triple therapy group had more aerobes than 
those off antibiotics but less than the Cloxacillin group.  Fifty percent of those on triple 
therapy had no strict anaerobes.  Faecal P. aeruginosa was not found in the controls but 
was found in 1 of the 7 off antibiotics.  Forty percent of the Cloxacillin group and 33% of 
the triple therapy group were positive for faecal P. aeruginosa (Roy et al, 1979).  This 
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study indicates that there is an alteration in the composition of the indigenous microflora 
in CF children both on and off antibiotic therapy.      
  
The presence of excessive bile acids and excessive CHO in the colon as well as the 
frequent use of antibiotics would have a negative impact on both the total amount and the 
composition of the GIT microflora.  This reduction of and alteration in the GI microflora 
could feasibly suppress the immune system predisposing the CF patient to lung 
infections.  Supplementation with probiotics may help normalise the GI microflora 
increasing resistance to lung infections.   
 
2.6 THE USE OF PROBIOTICS IN THE PREVENTION OF LUNG INFECTIONS 
 
According to Gorbach (2002) there is mounting evidence of a potential role of probiotics 
in the prevention of acute respiratory infections among children in day care centres. 
 
2.6.1 Use of probiotics in the prevention of respiratory infections in healthy children. 
 
Gorbach (2002) cited a recent placebo controlled study in Brazil (authors not mentioned) 
where probiotics (type not mentioned) given in milk to children in day care centres 
showed a significant prevention of respiratory infections.   
 
Hatakka et al (2001) conducted a randomised, double blind, placebo controlled study in 
Finland for a period of 7 months.  Their objective was to establish whether milk fortified 
with Lactobacillus rhamnosus Gorbach & Goldin (LGG) reduced the occurrence of both 
GI and respiratory infections in children aged 1 to 6 years attending day care centres.  
The study was done in winter when there is a high incidence of infections.   
 
Hatakka’s study group consisted of 282 healthy children and the control group consisted 
of 289 healthy children.  The average daily consumption of milk in both groups was 260 
ml.  The Lactobacillus milk contained 5-10 x 105 cfu of LGG.  A daily symptom diary 
was filled in by the parents documenting respiratory symptoms, fever, runny nose, sore 
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throat, cough, chest wheezes, ear ache as well as GI symptoms such as diarrhoea, 
vomiting and stomach ache.  Absences from the day care centre were recorded.  Stool 
samples were taken at the start, midway and conclusion of the study.  The recovery of 
LGG was assessed in a random sample of 100 stools to confirm compliance.  Fifty eight 
children dropped out the study - no reason was given.  In the study group there were 
significantly fewer days absent and significantly fewer children were prescribed 
antibiotics for respiratory infections.  However 15% of the children in the control group 
were found to be positive for LGG at the end of the study probably because LGG 
products are widely available in Finland.  This could have concealed a greater effect of 
LGG in the prevention of respiratory infections as some of the control group were 
inadvertently supplementing with LGG.      
 
2.6.2 The use of probiotics in the prevention of respiratory infections caused by 
Pseudomonas aeruginosa. 
 
Alvarez, Herrero, Bru & Perdigon (2001) studied the effect of Lactobacillus casei or 
yogurt on 3 week old mice (number unknown, design of trial unknown) to establish 
whether either one reduced the incidence of lung infections from P. aeruginosa.  Their 
results showed that the clearance from the lung of P. aeruginosa improved (significance 
not stated) and that the phagocytic activity of the alveolar macrophages increased in a 
dose-dependant manner (significance and dose not stated) with both L. casei and yoghurt.  
The white blood cell differential counts remained unchanged.  These normally increase in 
the presence of infection. 
 
Guarino (2002) used LGG supplementation in 30 CF children in Italy in a randomised, 
blinded, cross over trial (pending publication).  The children had a mean age of 9 years 
(SD±5).   Twenty out of 30 were colonised with P. aeruginosa.  They were given an oral 
rehydration solution with or without LGG for a period of 6 months and then crossed over 
for another 6 months.  The dose of LGG was not stated.  The results showed a reduction 
in the incidence of respiratory infections in all groups but particularly in the P. 
aeruginosa group (Figure 3).  The duration of pulmonary exacerbations decreased in the 
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P. aeruginosa group (Figure 4).  A reduction in abdominal pain was experienced in 7 out 
of 9 of the children (Figure 5).  In addition there were improvements in both steatorrhea 
and weight gain in the groups taking the LGG (Figure 6).  The significance was not 
stated.   
 
The limited trials on mice and children have indicated that probiotics (specifically LGG 
and  L. casei) may play a role in the prevention of lung infections in both healthy people 


























Figure 3  The effect of Lactobacillus 
rhamnosus Gorbach and Goldin in cystic 
fibrosis children and total number of 
infections (Guarino 2002)   
Figure 4  The effect of Lactobacillus 
rhamnosus Gorbach and Goldin in cystic 
fibrosis children and number of  infections 














Figure 6  The effect of Lactobacillus 
rhamnosus Gorbach and Goldin in 
cystic fibrosis children and percent 
weight gain (Guarino 2002) 
Figure 5  The effect of Lactobacillus 
rhamnosus Gorbach and Goldin in cystic 
fibrosis children and episodes of 





2.7     CHOOSING A PROBIOTIC 
 
The most clinically tested probiotic to date is LGG (Goldin, Gorbach, Saxelin, Barakat, 
Gualtieri & Salminen 1992).  However LGG is only available in SA as part of a probiotic 
“cocktail”.   Bioflora (Bioforce SA) contains Lactobacillus rhamnosus as well as 
Lactobacillus delbrueckii, Lactobacillus bulgaricus and Streptococcus thermophilus.  
Culturelle (Pharma Dynamics) contains Lactobacillus rhamnosus and Bifidobacterium 
longum in combination with a prebiotic (fructo-oligosaccharide).  For the purposes of 
research it would be more informative to test the effect of a single species rather than a 
mix of species as probiotics seem to have differing effects and potencies.  This means 
that LGG would need to be imported for the trial which would be costly.  In addition if 
the clinical trial proved to be of significant benefit, the local CF patients would not be 
able to continue with LGG after the trial.   
 
L. casei is available in a yoghurt sold in the Gauteng area of SA.  The concentration of 
bacteria in SA yogurt varies greatly (Louren, Viljoen & Jooste 2000).  As with any other 
yogurt the concentration of L. casei would not be constant in the yoghurt as it would vary 
according to shelf temperature and length of storage time (Lourens, Viljoen & Jooste 
2000).  The L. casei in yoghurt also has a short shelf life versus the longer shelf life of 
probiotics marketed as capsules or tablets.  The yoghurt would also not be easily 
accessible for the trial or for use by the local CF patients after the trial. 
 
As neither of the 2 probiotics investigated in the treatment of lung infections is available 
in SA, an alternative which meets the criteria for a successful probiotic needs to be 
selected.  According to Gorbach (2000) criteria for a successful probiotic were drawn up 





Table 4  The major criteria for a successful probiotic (Gorbach 2000, & Bengmark 2000) 
Human origin 
Acid and bile stable 
Colonize the human intestinal tract 
Adhere to human intestinal cells 
Produce antimicrobial substances 
Antagonistic to pathogenic bacteria 




Potential single probiotic supplements currently available in South Africa include L. 
reuteri and Saccharomyces boulardii (Interflora).   
 
To offer a health benefit the bacteria needs to be of human origin (Salminen 2001) as 
there are species dependant health effects.  As S. boulardii is a yeast of non-human origin 
it does not meet the criteria for a successful probiotic and was therefore not considered 
suitable for use in the study reported in this dissertation on CF patients in KZN.  L. 
reuteri is of human origin as it is a normal inhabitant of the GIT of healthy humans 
(Wolf, Wheeler, Ataya & Garleb 1998) and is frequently identified in the faecal samples 
of healthy volunteers (Jacobsen, Rosenfeldt Nielsen, Hayford, Moller, Michaelsen, 
Paerregaard, Sandstorm, Tvede & Jakobsen 1999). 
 
The probiotic needs to be acid stable to ensure survival through the stomach.  According 
to Bengmark (1998) Lactobacillus are acid loving.   The probiotic needs to be bile stable 
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to ensure survival through the intestines and to maintain adhesiveness (Bengmark 1998).  
This is particularly important in CF patients as they have much higher concentrations of 
bile acids in the colon.  L. reuteri is not only bile resistant but also releases bile salt 
hydrolase which enhances bile salt digestion and appear to decrease the bioavailability of 
the harmful bile salts (De Boever, Wouters, Verschaeve, Berckmans, Schoeters & 
Verstraete 2000). 
 
It has been clearly established that L. reuteri colonizes the human GIT.  Shornikova, 
Casas, Mykkanen, Salo & Vesikari (1997) established that supplementation with L. 
reuteri at doses of 107 to 1010 cfu per day established colonisation in children aged 6 to 
36 months suffering from rotavirus diarrhoea.  Salminen (2001) showed that L. reuteri 
colonised in the human GIT. 
 
After colonization of the GIT by the probiotic, adhesion is important.  The complex 
adhesion studies performed by Jacobsen et al (1999) showed that L. reuteri adhered 
strongly to the Caco-2 human epithelial cell lines in vitro. 
 
The production of antimicrobial substances is important for pathogen inactivation in the 
GIT as well as for normalisation of the GIT flora (Jacobsen et al 1999; Gorbach 2000).  
Lactobacilli in general are very efficient at counteracting gram negative bacteria 
(Bengmark 1998).  Jacobsen et al (1999) showed that L. reuteri broadly inhibits 
pathogenic bacteria.  According to Thornball (2000) L. reuteri produces reuterin and 
reutericyclin which appear to be effective antimicrobial agents (Figure 7).  It was clearly 
demonstrated at the European Society for Parenteral and Enteral Nutrition Congress by 
Sinkiewicz (2000) cited by Thornball (2000) that L. reuteri inhibited the growth of both 
Salmonella and S. aureus.   Nollet, Pereira & Verstraete (1999) showed that the 
antimicrobial range of reuterin includes both gram positive and gram negative bacteria, 
yeasts, fungi, protozoa and viruses.  They commented that L. reuteri from a human was 
more effective against Salmonella from a human, while L. reuteri from a rat was more 









Figure 7  Different strains of Lactobacillus reuteri showing an inhibiting effect on the 
growth of Salmonella – the dark zones around the colony show areas where the 
pathogens can not grow (Thornball 2000). 
 
Although L. reuteri has not been used in any trials studying its effect on lung infections, 
there are clinically validated and documented health effects, particularly in the treatment 
of rotavirus induced diarrhoea.  Shornikova et al (1997) showed a significant 
improvement in watery diarrhoea in hospitalised children.  The children were divided 
into 3 groups who received either L. reuteri at 107 cfu or L. reuteri at 1010 cfu or placebo 
for five days.  Both the L. reuteri groups showed a significantly reduced duration of 
watery diarrhoea.  The duration of diarrhoea was 2.5 days in the placebo group, 1.9 days 
in the 107 L. reuteri group and 1.5 days in the1010 L. reuteri group.  Ruiz-Palacios, Tuz, 
Arteaga, Lourdes Guerrero, Dohnalek & Hilty (1996) studied 408 healthy bottle fed 
children to assess whether probiotics could reduce the incidence of community-acquired 
diarrhoea.  The first group (placebo) received milk as part of their diet.  The second group 
received milk with added L. reuteri, Lactobacillus acidophilus and Bifidobacteria 
infantis.  The third group received milk with L. acidophilus and Bifidobacteria animalis.  
Both groups receiving the probiotics had a significantly reduced risk of diarrhoea.  
Thornball (2000) stated that it is generally well established in the literature that the use of 
Lactobacillus is safe for human consumption and Lactobacillus has been classified as 
Generally Recognised As Safe (GRAS).  Salminen, Von Wright, Morelli, Marteau, 
Brassart, de Vos, Fonden, Saxelin, Collins, Morgensen, Birkeland & Mattila-Sandholm 
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(1998) stated that the best test for food safety is a well documented history of safe human 
consumption.  If this criteria is used L. reuteri, which has been on the market since 1980, 
has no adverse reports. 
 
There has been some concern that probiotic bacteria may translocate and become 
pathogenic in immune suppressed individuals.  Thornball (2000) showed some bacterial 
translocation of L. acidophilus, L. casei and LGG in immune suppressed mice but there 
was no translocation of L. reuteri.   
 
With high doses of L. reuteri (1011 cfu) mild flatulence was the only GI symptom noted 
in 30 healthy male adults over a period of 21 days (Wolf, Garleb, Ataya & Casas 1995).  
No other side effects have been reported in the scientific literature. 
 
In summary the literature shows that L. reuteri meets all the criteria of a successful 
probiotic making it a suitable choice for the trial as it is of human origin, is acid and bile 
stable.  It colonizes the human GIT, adheres to human intestinal cells, produces 
antimicrobial substances, is antagonistic to pathogenic bacteria, has been clinically 
validated and has documented health effects.  It is also safe and has a guaranteed viable 











2.8 DOSE OF PROBIOTIC 
 
Ruiz-Palacios et al (1996) classified 106 cfu per ml as a low dose, 108 cfu per ml as a 
medium dose and 1010 cfu per ml as a high dose of L. reuteri.  When using probiotics 
therapeutically a medium to high dose is usually prescribed.  Different disease conditions 
however may need different therapeutic doses to exert a positive effect (Van der Waaij 
1999).  Wolf et al (1998) gave L. reuteri or placebo to 39 HIV-positive patients, aged 18 
to 60 years, in a dose of 1010 cfu per ml per day for 21 days.  It was established that the 
faecal levels of Lactobacillus was much lower in HIV-positive group compared to 
healthy subjects even after consumption of 1 x 1010 cfu/day, implying that high doses 
may be necessary in certain disease conditions. 
 
As no studies have been done using L. reuteri in CF patients the optimal dose is 
unknown.  The study investigating the effect of LGG on the incidence of respiratory 
infections in healthy children used a low dose of between 5 to 10 x 105 cfu per day 
(Hatakka et al 2001).  Although it may be appropriate to use a high dose in CF patients 
due to the abnormal substrates entering the colon and the frequent use of antibiotics, 
safety has not been established in CF patients and it would appear prudent to use a more 
conventional dose of 1 x 108 cfu per day. 
 
L. reuteri is available in a dose of 1 x 108 cfu in both tablet and straw form.  The 










In spite of the improvement in treatment, malnutrition in CF patients, especially in those 
over 10 years of age, is still a significant problem locally if the studies done at the Red 
Cross Hospital are representative of the South African CF population as a whole.  As the 
CF patient reaches adolescence, compliance to treatment decreases resulting in an 
increase in the severity of malnutrition and the risk of developing drug resistance to the 
few effective antibiotics available.   
 
Increasing evidence is indicating that the indigenous microflora plus supplementation 
with probiotics may have a significant positive impact on the immune system.  The use of 
probiotics may be even more beneficial in CF patient as their indigenous microflora is 
likely to be deranged from the abnormal food substrates entering the colon as well as the 
routine use of antibiotics.  Limited studies on the use of LGG as a probiotic in the 
treatment of respiratory infections in both healthy children and those with CF have shown 
a significant decrease in the incidence of infections.  This in turn would decrease the use 
of antibiotics reducing the risk of resistance (Gorbach 2002, Hatakka et al 2001, Guarino 
2002).   
 
Although LGG is the most commonly used and most commonly researched probiotic it is 
not available in SA as a single strain.  L. reuteri which is available appears to be a 
suitable alternative as it meets all the criteria of a potential probiotic.  A moderate dose of 
1 x 108 cfu per day appears prudent as the use of probiotics and their safety has not been 





CHAPTER 3:  METHODOLOGY 
 
The primary purpose of the study was to determine whether supplementation with a 
probiotic (L. reuteri) would improve anthropometric measurements, reduce the incidence 
and shorten the duration of lung infections and would maintain or prevent deterioration in 
lung function in CF patients attending the CF clinics in KZN Durban.  The secondary 
purpose of the study was to compare the nutritional status, at the end of the study, as 
determined by anthropometry (percentage weight for height) of CF patients attending CF 
clinics in KZN Durban with CF patients attending CF clinics in Cape Town from the 
published data by Westwood & Saitowitz (1999). 
 
3.1 DURBAN STUDY 
 
3.1.1 Study Design 
 
This study was carried out in two parts.  The primary study purpose was experimentally 
determined by a study in Durban that was a randomized, double blind, placebo controlled 
cross over trial run over the period of a year.  The patients were randomly allocated to 
either placebo or probiotic for the first 6 months and then crossed over.  The group that 
received the probiotic first was group A while group B received the placebo in the first 
six months.   
 
The study started in January 2005.  After the study had begun it was pointed out by 
Lawson (2006) that the normal growth patterns of children should have been established 
before intervention with the probiotic.  For group B the normal growth patterns could be 
established as they were on the placebo for the first six months before intervention with 
the probiotic for the second 6 months.  To establish normal growth patterns the height 
and weight measurements for group A who were on the probiotic in the first six months 
(group A) was taken retrospectively from the medical records of the patients.  This data 
was available as the same two dieticians who had taken the measurements at the start of 
the study take all the anthropometric measurements at the CF clinics.  See Figure 8 for 
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flow diagram.  This is why data is presented in the results as the measurement eg weight 
taken six months before probiotic to start of probiotic (1st six months before intervention 
that is at baseline) and start of probiotic to the end of probiotic (2nd six months 
intervention with the probiotic).  The difference between the six months before probiotic 
to start of probiotic (changes in weight while on placebo) and start of probiotic to end of 
probiotic (changes in weight while on probiotic) were shown in the tables in chapter four.  
All the other measurements were taken at the start of the study (January 2005), middle 
(June 2005) and end of the study (December 2005).   
 
Mid arm circumference and TSF measurements were taken at the start and end of the 
study only.  Unfortunately these measurements were not retrospectively available.  All 
other measurements that is incidence and duration of lung infection, duration on 
antibiotics, lung function, sputum analysis and symptom diaries were taken at the actual 
start of the study (Jan 2005), at crossover six months later and at the end of the study.  
Data presented in the results chapter were for group A on probiotic January to June and 
for group B on probiotic July to December.  Group A of probiotic July to December and 
group B January to June.   
 
The secondary purpose of the study was to compare the nutritional status of the patients 
attending the CF clinics in KZN Durban (at the end of the study) with the patients 
attending the CF clinics in Cape Town (data collected in 1996).  The data from the Cape 
Town clinics was obtained from the publication by Westwood & Saitowitz (1999).  This 
is the only anthropometric data published for CF patients in SA.  Westwood & Saitowitz 
(1999) reassessed the nutritional status of the CF population at the Red Cross Hospital in 
1996.  Their study on 45 patients included the entire population of this CF clinic minus 
those under 2 years old, those with very severe lung disease and those who lived more 
than 60 km away.  As 7 did not complete the 3 day weighed food record (18.4%), a final 





The studies had a similar number of patients and exclusion criteria so were comparable.  
As Westwood & Saitowitz (1999) used a modification of the Waterlow and Rutishauser 
classification for growth measurements (Ramsey et al (1992) based on percentage 
expected weight for height (% EWFH) the Durban data was converted to %EWFH to 
enable the comparison.  The weight, height, MAC and TSF readings from the end of the 
study (Dec 2005) were used as this was the most recent data from Durban.   
 
3.1.2 Sample population 
 
All the CF patients who had attended either the private CF clinic held at St Augustine’s 
Hospital or the state clinic held at Addington Hospital (both in Durban) for at least 1 year 
were asked to take part in the study.   
 
The secretary of the KwaZulu-Natal Cystic Fibrosis Committee provided a list of contact 
details of all known CF patients in the province.  Dr Egner, the CF pediatrician at St 
Augustine’s Hospital, supplied the details of any additional CF patients in his practice 
that were not on the list.  In total number 42 patients with CF were located.  Six were 
excluded from the study at this stage as they were below six years of age and were too 
young to perform the lung function test.  Another exclusion criterion was a Shwachman 
score3 of less than 40.  One patient was excluded who had a score below 40.  This left 35 
patients suitable for inclusion in the Durban study.   
 
Three weeks before the start of the Durban study a letter of introduction was sent to these 
35 CF patients explaining the purpose of the study, what would be required of them and 
asking them to phone the CF clinic dietician to confirm participation (Appendix A).  A 
week before the January clinics all patients that had not responded were reached by 
telephone and asked to participate.   
 
                                                 
3 The Shwachman score was used to measure the severity of lung disease.  The questionnaire consists of 
four sections, each with a rating from 0-25.  The four sections included are general activity, physical 
examination, nutrition and chest x-ray.  A score of 86-100 is excellent, 71-85 is good, 56-70 is mild, 41 -55 
is moderate and 0-40 indicates severe lung disease.   
 40
As it was the holiday season a few were still on holiday so it was decided that these 
patients could start the study in February.  These patients were phoned again a week 
before the February clinic to remind them about the study.   
 
A total of twenty-three of the thirty five (66%) patients consented to be involved in the 
study.  Reasons given by either the CF patients themselves or by the parents of minors as 
why they did not want to participate in the study are listed in Table 5. 
 
Table 5  Reasons for not participating in the study 
‘too busy’ and ‘no time’ 
‘do not attend the clinics’ regularly’ 
‘too inconvenient to be part of the study’ 
‘appreciating & admiring what you are doing but not for me’ 
‘too much effort to be part of the study’ 
 
3.1.3  Randomization and blinding 
 
In the Durban study the two study groups were matched for both sex and age.  Firstly the 
participants (n=23) were grouped into males and females as males live longer than 
females and seem to have less severe lung infections.  Each group of males and females 
were then ranked in order of birth date because there is deterioration of lung function 
with age.  The pharmacist then allocated every second person in the group of males and 
every second person in the group of females to Group A (n=11).  Those remaining 
formed Group B (n=12).  Group A received L. reuteri for the first 6 months and then 
placebo for the last 6 months and Group B received placebo for the first 6 months and 
then L. reuteri for the last 6 months.  The dose of L. reuteri was of 1 x 108 cfu per straw 
per day This was done by the pharmacist to ensure that the process was double blinded 
for both the researcher and CF patients.  The pharmacist kept a record of which patients 
were in each study group until blinding was broken at the end of the 12 month study 
period.  As the study was a crossover no control was necessary as the patients acted as 





The intervention of the study was that patients were to take one straw a day either 
probiotic (1 x 108 cfu dose) or placebo.  It was decided to use the straw as it was felt that 
in this population group they would be less likely to be compliant if they were required to 
take yet another tablet.  Placebo straws were available for use at the time but no placebo 
tablet.   
 
The technical properties of L. reuteri are good as the tablet has a shelf life of 18 months 
while the L. reuteri containing straw has a shelf life of 12 months.  Viable concentrations 
are guaranteed up until the expiry date if stored in a refrigerator (Shornikova, Casas, 
Mykkanen, Salo & Vesikari 1997).   
 
To ensure blinding the straws had been packed into the bags by the same pharmacist who 
randomized the groups.  Sufficient straws were issued for 6 months (180 straws).  In an 
attempt to monitor compliance patients were asked to keep the used straws and to bring 
back both the used and unused straws for the 6 month period.  Straws were issued for a 6 
month period rather than on a monthly basis as the CF patients varied in their timing of 
clinic visits.   
 
3.1.5 Pilot study 
 
No formal pilot study was done as this masters study was the pilot study for a multicentre 
trial.   
 
3.2 STUDY METHODS AND MATERIALS  
 
The following variables were obtained; weight, height, midarm circumference, triceps 
skinfold thickness, lung function, lung infection rate, sputum samples, a food frequency 
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questionnaire regarding pre and probiotic use was asked and a symptom diary was 
collected.   
 
3.2.1 Measurement techniques 
 
The dieticians measured the weight, height, MAC and TSF.  One dietician took a set of 
readings on each patient.  The other dietician then repeated the measurements on the 
same patient to confirm that the readings were consistent.  There was no significant 
difference between the two dietician’s readings for weight, height, MAC and TSF for 
each patient for the first period and for the second period with the p value are given in 
each section.  This was done in an attempt to validate the readings between the two 
dieticians.  Repeatability studies were not conducted in this pilot study.  The same 
equipment was used during the 12 month trial period.  As there was only one 
physiotherapist for the 12 months of the study and she used the same equipment 
MicroLAB 2000 3300 (Micro Medical) for the entire length of the study validity and 
reliability studies were not undertaken.  The food frequency questionnaire regarding pre 
and probiotic use was piloted on ten non CF subjects before the trial began to ensure that 
the format and questions were understandable.  No changes needed to be made to the 
questionnaire. 
 
3.2.1.1  Weight 
 
Weight was measured using a portable Masskot scale which weighed a maximum of 150 
kg and a minimum of 50g.  The scale was calibrated by the Discipline of Dietetics and 
Human Nutrition Pietermarizburg before the study began.  The same scale was used 
throughout the study.  The patient was weighed in light clothing, barefoot and after 
voiding.  They were asked to step onto the center of the scale, with their weight evenly 
distributed on both feet, and to look up and directly ahead.  Their weight was then 
recorded (Norton & Olds 1996).  The second dietician repeated the weight measurement.  
If the readings differed by a 100 g a third reading was taken.  The average of the two 
similar readings was used.  The time of day that the weight was measured was also noted.     
 43
 
There was no significant difference between the two dietician’s readings for weight for 
each patient for the first period (p=0.669) and for the second period (p=0.326).  The mean 
of the 2 weights was used.      
 
3.2.1.2  Height 
 
Height was measured using a portable stadiometer (as approved by ISAK, the 
International Society for the Advancement of Kinanthropometry).  The same stadiometer 
was used throughout the study. 
 
The free-standing stature method described by Norton & Olds (1996) was used.  The 
patient was asked to take off their shoes and then stand on the base of the stadiometer 
with their back against the stadiometer.  Their heels, buttock, upper part of the back and 
back of the head was in contact with the stadiometer.  They were asked to stand erect 
with their heels together and arms hung naturally by the sides.  The subjects head was 
placed in the Frankfort plane.  They were asked to take a deep breath while the headpiece 
was lowered onto their vertex and a reading was taken during inhalation and recorded.  
The second dietitian repeated this measurement.  If the readings differed by 2 mm a third 
reading was taken. The average of the two similar readings was used.  The time of day 
that the height was measured was also noted.     
 
There was no significant difference between the two dietician’s readings for height for 
the first period (p=0.278) and for the second period (p=0.108). 
 
3.2.1.3  Mid arm circumference 
 
The patient was asked to stand in a relaxed position with arms hanging loosely.  All land 
marks were done on the right side of the patient as described by (Norton & Olds 1996).  
First the acromial point was located at the superior and lateral border of the acromion 
process.  This was then marked midway between the anterior and posterior borders of the 
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deltoid muscle when viewed from the side.  The head of the radius was then located by 
using the left thumb or index finger, palpating downwards in the lower portion of the 
lateral dimple of the elbow.  A line was drawn between the acromial and radiale 
horizontal to the long axis of the humerus at the mid-acromiale-radiale.  The distance 
between these two points was measured using an anthropometric tape and the mid point 
was marked.  The other dietician checked that the tape was straight.  The mid arm 
circumference was measured at the mid point using an anthropometric tape and recorded.  
The second dietician repeated this measurement.  If the measurements differed by 2 mm 
they were repeated.  The average of the two similar measurements was used.   There was 
no significant difference between the two dietician’s readings for MAC for the first 
period (p=0.347) and for the second period (p=0.110).   
 
3.2.1.4  Triceps skinfold thickness 
 
At the mid point the horizontal line was extended to the posterior surface of the arm, 
where a vertical line at the most posterior surface was marked to intersect with the 
horizontal line.  This was the point where the triceps skinfold was measured (Norton & 
Olds 1996). 
 
The skinfold was raised with the left thumb and index finger on the marked posterior 
mid-acromiale-radiale line.  The fold was vertical and parallel to the line of the upper 
arm.  The skinfold was taken on the most posterior surface of the arm over the triceps 
muscle when viewed from the side.  For the measurement, the arm was relaxed with the 
shoulder joint slightly externally rotated and the elbow extended by the side of the body.  
The skinfold was raised on the landmark.  The calipers were placed 1 cm below the 
landmark, after a two seconds lapse the first reading was taken and recorded.  The second 
dietician took the second reading after a minimum of 5 minutes had passed to allow the 
skinfold to return to normal.  If the readings differed by 2 mm they were repeated.  An 
average of the 2 similar readings was used.  There was no significant difference between 
the two dietician’s readings for the TSF readings for the first period (p=0.080) and for the 
second period (p=0.609).   
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3.2.1.5  Lung infection rate 
 
The incidence of lung infection was the number of new lung infections experienced over 
the 12 month study period for which the doctor wrote up antibiotic treatment.  
Continuous antibiotic treatment was not included as a new infection.  Five patients 
received continuous antibiotics for the whole 12 months of the study (probiotic and 
placebo) while one patient received continuous antibiotics during the second six month 
period while on placebo.  
 
3.2.1.6  Lung function  
 
Forced expiratory volume in 1 second and FVC were measured by the same 
physiotherapist.  One or 2 readings were taken and the better of the two readings were 
used in the study.  If the CF patient only managed 1 FEV1 and FVC reading this result 
was used.  The equipment used by the physiotherapist was a MicroLAB 2000 3300 
(Micro Medical).  The patient stood in front of the machine, inhaled a full breath, then 
closed their lips around the mouthpiece and blew out as hard and fast as possible until 
they had expelled all the air in their lungs.  The inspiration was full and unhurried and the 
expiration was continued without pause.  The patient was verbally encouraged to blow as 
hard and fast as possible by the physiotherapist.   Two readings were taken if the patient 
was able to do two.  Occasionally the patient was only able to do the test once – in this 
case this was the only reading used.   
 
3.2.1.7  Sputum 
 
The sputum was assessed quantitatively for pathogenic bacteria (Table 6).  The 
laboratories were unwilling to release the methodology as they claimed it was 






Table 6  Analysis of bacterial type in sputum   
Gram stain Final 
Pus cells 
Epithelial cells 
Gram negative bacilli 
Gram positive cocci 
Mixed oropharyngeal flora 
Ps aeruginosa (dry) 
Ps aeruginosa (mucoid) 
Yeast, not Candida alblicans 
S. aureus  
B. cepacia 
H. influenzae  
 
The sputum score at baseline, at the end of first period and at the end of second period 
was calculated as the sum of responses (on a scale of 0 to 4) for P. aeruginosa (dry and 
muciod), S. aurens, and B. cepacia.  These three were selected as they are the most 
serious and problematic for CF patient (Hart & Winstanley 2002).  The higher the score, 
the more bacteria were present.  
 
3.2.1.8  Food frequency questionnaire regarding pre and probiotic use 
 
Questions regarding food supplements and foods (particularly yogurts) where asked of 
the CF patients.  This was not a diet history as the diet/food intake of the subjects in the 
study was not looked at.  To ensure standardization, the questionnaire was administered 
and recorded by the same dietician.  Questions were asked as to the use and frequency of 
food supplementation and consumption of yogurt, as well as vitamin and mineral 
supplementation.  Subjects were asked if they were brand specific when buying yogurt so 
that the type of probiotic found in specific brands could be identified (Appendix E).  The 
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questionnaire used to establish whether the CF patients consumed significant amounts of 
either pre or probiotics. 
 
3.2.1.9  Symptom Diary  
 
To ensure standardization the purpose of the symptom diary and how to fill it in was 
explained to the patient by the same dietician.  Patients were asked to record daily 
whether they had experienced fever, runny nose, sore throat, cough, chest wheeze, 
earache, thrush, diarrhea, constipation, vomiting and stomach ache Appendix C.  The 
scoring system was one tick for mild symptoms, two ticks for moderate and three ticks 
for severe symptoms.  The total number of ticks was recorded for each symptom per 
month. 
 
3.2.1.10 Shwachman Score 
 
The Shwachman Score was used to measure the severity of lung disease.  The 
questionnaire consists of four sections, each with a rating from 0-25.  The four sections 
included are general activity, physical examination, nutrition and chest x-ray.  A score of 
86-100 is excellent, 71-85 is good, 56-70 is mild, 41 -55 is moderate and 0-40 indicates 
severe lung disease.   
 
 
3.2.2 Data collection 
 
3.2.2.1  Prior to the start of the study 
 
A meeting was held with the doctors, the physiotherapist and the dieticians involved in 
the KZN Durban CF clinics to advise every one of the standards and definitions required 
for the study.  The collation sheets (see Appendix B) that the doctors were required to fill 
in during the study were explained to them and any questions answered regarding the 
filling in of these collation sheets.  They were asked to record the type of treatment and 
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duration of treatment of lung infections at each visit or hospital admission on the 
collation sheets (Appendix B).  As antibiotics would destroy the probiotics, information 
regarding the type and amount of antibiotics was requested.  They were asked not to 
script probiotics during the course of the study.   
 
3.2.2.2  Start of the study 
 
On arrival at the clinic before signing the consent form, each participant had the study 
explained to both them and their family in detail.  They were shown the straws containing 
the probiotic, how to use them and the symptom diary (see Appendix C) that they needed 
to fill in daily. They were asked if they had any questions regarding the study and 
whether they were willing to sign the consent forms (see Appendix D1 & D2).  Only 
once the consent forms were signed the measurements (described below) were taken.  See 
Figure 8 page 39.   
 
The physiotherapist did 2 FEV1 and FVC readings on each CF patient.  In some cases 
however the CF patient could only do 1 FEV1 and FVC reading.  These results were 
recorded in Appendix J.  At the end of the FEV1 and FVC tests the CF patient was 
requested to produce a sputum sample which was then sent to the laboratory for microbial 
analysis.  Not all patients were able to produce sputum at the start of the trial.  In this case 
the sputum sample collected at the next clinic was used.   
 
The dieticians measured the height, weight, MAC and TSF.  Because of the potential 
carry over effect of the probiotic on the patient’s growth it was necessary to determine 
the weights and heights of those that took the probiotic first (Group A), for six months 
prior to the start of the probiotic.  Baseline referred to the first set of measurements that 
was taken six months prior to starting the probiotic.  Group A started the probiotic first 
and these baseline measurements were taken from the patient’s medical record.  This was 
six months before the trial started.  For group B, the group that started the placebo first, 
these measurements were taken at the start of the study (that is start of placebo in January 
2005) as this was six months before the start of the probiotic. This data for group A was 
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taken retrospectively from the patients medical records at the end of the study after 
blinding had been broken so that their growth could be assessed independently from the 
effects of the probiotic.  All other data (lung function, infection rate) was taken from the 
starting point of the study - the first group that was on probiotic and then placebo for the 
12 months (group A) and the second (group B) that received placebo then probiotic.   
 
A food frequency questionnaire (Appendix E) was asked regarding the consumption of 
pre and probiotics.  This was not a diet history as information was needed to establish the 
use (if any) of a pre and probiotic consumption by the CF patients.  The questionnaire 
was completed by the interviewer.  The participants were asked not to take any new 
supplements during the trial without informing the dietician.   
 
The purpose of the symptom diary (see Appendix C) was explained as well as how to fill 
it in.  Patients were also asked to contact the dietician if they consulted a doctor other 
than one of the CF doctors during the trial for treatment of a lung infection.  If they did 
consult a doctor that was not at the KZN Durban clinics a letter (Appendix F) was faxed 
to the other treating doctor.  This letter informed the doctor about the study and requested 
information about the reasons for the CF patient’s visit and the medications prescribed. 
They were also requested not to prescribe a probiotic.  The Shwachman score was filled 
in by the doctor, physiotherapist and dietician (Appendix G).  The straws were then 
issued to the patients in a brown paper bag labeled with their name.   
 
3.2.2.3  During the first six months of the trial  
 
The CF doctors filled in the collation sheets each time they prescribed any antibiotic 
treatment for the CF patient.  The dieticians collected these.  The physiotherapist and 
dieticians encouraged the CF patients to use their straws and fill in their symptom diary.  
Just before the 6 month clinic the CF patients were sent a letter reminding them to attend 




3.2.2.4  At the 6 month crossover period 
 
After 6 months the patients returned their straws and symptom diary.  The straws were 
counted by the dietician and a record was kept of the used and unused straws per patient.  
If both the straws and the diary were returned they received R75 – they were not paid if 
either the straws or diary was not returned.  They were then crossed over to receive the 
other straws.  Again a 6 months supply of straws was issued to each patient in a brown 
paper bag labeled with their name.   
 
The same physiotherapist repeated the lung function measurements and collected a 
sputum sample for microbial analysis.  The same dieticians repeated the weights and 
heights. 
 
3.2.2.5  During the second six months of the trial  
 
The CF doctors continued to fill in the collation sheets each time they prescribed any 
antibiotic treatment for the CF patient.  The physiotherapist and dieticians attempted to 
encourage compliance.  Three weeks before the end of the trial, a reminder was sent out 
asking each patient to bring their used and unused straws and symptom diary to the clinic 
(Appendix I).  
 
3.2.2.6  At the end of the 12 month study period 
 
At the clinic the same physiotherapist took the better of 2 FEV1 and FVC readings and 
collected sputum.  The same dieticians repeated the height, weight, MAC and TSF on 
each patient, using the same equipment and techniques as in the beginning of the study.  
The data was recorded on a form (Appendix J). 
 
Both the symptom diary and the used and unused straws were collected.  Each participant 
was then thanked for their cooperation and again paid R75 and informed that they would 
receive a copy of the results of the study as soon as the data was processed.   
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The collation sheets were collected from the doctors.  The straws from the second six 
month period were counted and recorded by the dietician.  The data was entered into the 
database.     
 
3.3 DATA ANALYSIS 
 
The data was analysed in two different ways.  Measurements relating to growth (heights 
and weights) were taken at baseline, which was 6 months before the start of probiotic, 
taken 6 months later at the start of the probiotic, and at the end of the 6 months on 
probiotic.  This group consisted of half of the study population (n=8) and was labeled 
Group A.  The other half of the study population (n=8) had the first set of growth 
measurement taken at the beginning of the study in January/February while starting on 
placebo for 6 months.  The next set of measurements were taken at the start of the 
probiotic, and the last set were done after taking the probiotic for 6 months.  This has 
been labeled baseline, start of probiotic and end probiotic in the tables that follow.  For 
the results and discussion the ‘on placebo’ time period refers to the 6 months not on the 
probiotic.  Measurements pertaining to lung infection and duration, lung function, 
antibiotic use, and the symptom diary was taken at the start of the study 
(January/February), at the cross over (June/July) and at the end of the study in 
December/January.  Group A started the probiotic first and then took the placebo while 
Group B started placebo first and then took the probiotic (Figure 8 page 39). 
 
Analysis of food frequency questionnaire 
The frequency of use for food supplements and yogurt plus the types consumed was 
calculated from the data. 
 
Height for age 
The height for age (HFA) percentile for those 20 years and below was read off the Centre 
of Disease Control Charts (CDC) 2000.  Using the correct height-for-age percentiles 
chart for sex, the 50th percentile for height for chronological age was found (this is the 




Percentage expected height for age= Actual height for age     x 100 
     Expected height for age 
 
For example if the actual height of a 10 year old girl is 126.8 cm and the 50th percentile 
for height and age is 138 cm then her %EHFA would be 126.8 cm divided by 138 cm and 
multiplied by 100 which equals 92%. 
 
Weight for age 
The weight for age (WFA) percentile for those 20 years and below was read off the CDC 
chart (2000).  Using the correct weight-for-age percentiles chart for sex, the 50th 
percentile for weight for chronological age was found (this is the expected weight for age 
EWFA), and the actual weight was expressed as a percentage of this.   
 
Percentage expected weight for age= Actual weight for age    x 100 
     Expected weight for age 
 
For example if the actual weight of a 10 year old girl is 23.6 kg and the 50th percentile for 
weight for age is 33 kg then her %EWFA would be 23.6 divided by 33 multiplied by 100 
which equals 72%.  
 
Weight for height 
The weight for height was calculated using Epi Info TM for those below 126 cm in height.  
This was only one subject (the youngest subject whose height was below 126 cm).  A file 
was generated for this subject.  Height, weight, MAC and TSF were then entered into this 
file for the starting point and 6 months later for this subject.  Epi Info TM then calculated 
the weight for height and Z-scores for this subject.  Percentage expected weight for 
height were then used for the rest of the subjects. 
 
Percentage Expected Weight for height 
The expected weight for height (EWFH) was calculated for those 20 years or below by 
reading off the CDC charts (2000) (FAO 1990).  Using the height-for-age and weight-for-
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age percentiles chart for the sex, the actual height of the subject was located on the chart.  
A line was then drawn from the actual height across until it intersected with the 50th 
percentile for height.  A line was then taken from the 50th percentile vertically down the 
age line.  Where this line intersected the 50th percentile for weight a horizontal line was 
then drawn back and the corresponding weight was recorded.  This was the EWFH.   
 
To work out the percentage expected weight for height (%EWFH) the actual weight of 
the child was taken and divided by the EWFH and then multiplied by 100 
Percentage expected weight for height= Actual weight  x 100 
         EWFH  
 
For example the actual weight of a 10 year old girl was 23.6 kg.  This is divided by 
EWFH which was 25 kg and then multiplied by 100 to equal 94% EWFH 
 
Percentiles  
The CDC 2000 percentile charts, weight for age and stature for age, were used to plot the 




Z-scores describe the distance that an individual measurement is away from the mean or 
50th percentile measured in terms of standard deviations (FAO 1990).  A Z-score equal to 
zero means that the measurement is on the 50th percentile, a positive (+) Z-score indicates 
the number of standard deviations above the 50th percentile and a negative (-) Z-score 
indicates the number of standard deviations below the 50th percentile.  Z-scores are used 
as indicators for malnutrition.  A height for age Z-score of <-1.0 to -1.99 indicates mild 
stunting, <-2.0 to -2.99 moderate stunting and <-3.0 to -3.99 severe stunting.  A weight 
for age Z-scores of <-1.0 to -1.99 indicates mild underweight, <-2.0 to -2.99 moderated 
underweight and <-3.0 to -3.99 severe underweight and a weight for height Z-score of, <-
1.0 indicates mild wasting, <-2.0 moderate wasting and <-3.0 severe wasting (Dibley, 
Staehling, Nieburg & Trowbridge 1987).  The data for each subject was entered into Epi 
Info TM so the Z-scores could be calculated. 
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Body Mass Index (BMI) 
The BMI is a relationship between weight and height.  It is calculated by taking the 
weight (kg) and dividing by the height (m) squared.   
 
BMI = Weight (kg) 
 Height (m 2) 
 
For example a 21 year old male has a height of 1.8 m and weighs 60 kg, his BMI would 
be 18.8. 
 
Body Mass Index Z-scores (BMIZ) 
BMIZ were also calculated by Epi Info TM.  Being a Z-score this is a reading that is the 
number of standard deviation away from the 50th percentile for BMI.  Epi Info TM version 
3.3.2 was used to calculate BMI and BMI for age Z-score.  Epi Info TM uses the 2000 
CDC-WHO growth charts. 
 
The data was captured into SPSS version 11.5 (SPSS Inc, Chicago, Ill, USA) and 
analysed.  Epi Info TM version 3.3.2 was also used to capture the anthropometric data and 
analysed.  As the numbers for the study were small an intention to treat analysis was 
used.  The 95% confidence intervals for rate estimates were calculated in EpiCalc 2000 
(version 1.02, Joe Gilman and Mark Myatt, Brixton Books).  The objectives, data 
collections and statistical analysis used in the study have been tabulated in Table 7. 
 
3.4 ETHICAL CONSIDERATIONS 
 
Ethics approval (Ref.: E048/04) was granted by the Nelson R Mandela School of 
Medicine on the 24th of November 2004 (Appendix K1).  Permission to use the State and 
private hospitals can be seen in Appendix K2.  Written consent forms from participants 




3.5 CAPE TOWN STUDY 
 
To show validity for comparison.  The secondary purpose of the study was to compare 
the nutritional status of the patients attending the CF clinics in KZN Durban (n=35) with 
the patients attending the CF clinics in Cape Town (n=38).  The data from the Cape 
Town clinics was obtained from the publication by Westwood & Saitowitz (1999).  This 
is the only anthropometric data published for CF patients in SA.  The studies had a 
similar number of patients and exclusion criteria so were comparable.  For the Cape 
Town study by Westwood & Saitowitz (1999) their CF population at the Red Cross 
Hospital in 1996 consisted of 45 patients as the entire population.  They excluded those 
under 2 years old, those with very severe lung disease and those who lived more than 60 
km away.  As 7 did not complete the 3 day weighed food record (18.4%), a final total of 
38 patients were included in that paper.  As Westwood & Saitowitz (1999) used the 
classification for malnutrition from the consensus committee of the CF Foundation 
(Ramsay et al 1992) based on percentage expected weight for height (% EWFH) the 
Durban data was converted to %EWFH to enable the comparison.  The weight, height, 
MAC and TSF readings from the end of the study (Dec 2005) were used as this was the 
most recent data from Durban.   
 
Table 7  Objectives, data4 collection and analysis 
Objective Data Collection Data Analysis 
To determine weight at baseline, 
start of the probiotic and end of 
probiotic for the group as a whole 
as well as by age and gender and 
to compare weight gained over 
the six months prior to and while 





Descriptive statistics and 
paired t test 
Calculation of 
anthropometric indices: 
WFA percentiles, WFA Z-
scores, % EWFA.  
                                                 





Table 7  Objectives, data collection and analysis continued 
To determine height at baseline, 
start of the probiotic and end of 
probiotic for the group as a whole 
as well as by age and gender and 
to compare height gained over the 
six months prior to and while 




Descriptive statistics and 
paired t test 
Calculation of 
anthropometric indices: 
WFH percentiles, WFH Z-
scores, HFA, % EHFA.  
BMI for age percentiles 
and BMI Z-scores 
To compare the percentage 
expected weight for height 
(%EWFH), mid arm 
circumference (MAC) and triceps 
skinfold thickness (TSF) in CF 
patients in Durban and Cape 
Town.  For the comparison to the 
Cape Town patients this data was 
obtained from the publication by 
Westwood and Saitowitz (1999)   
Weight 
Height 
Height for age and 
weight for age 






Saitowitz (1999)  
Descriptive statistics (mean 
and standard deviation) 
To determine and compare the 
incidence and duration of lung 
infections while taking the 
probiotic and while taking the 
placebo. 
Number of lung 
infections filled in by 
the KZN Durban CF 
doctors at each clinic 
visit 
Incidence rate and 95% 
confidence interval 
Descriptive statistics (mean 
and standard deviation) 
To determine and compare the 
mean change in lung function 
while taking the probiotic and 
while taking the placebo 








Table 7  Objectives, data collection and analysis continued 
To determine the number of CF 
patients in the study colonized 
with P. aeruginosa 
Sputum results Descriptive statistics 
To determine and compare the 
change in the presence and 
quantity of P aeruginosa (dry and 
mucoid), S. aurens and B. cepacia 
in the sputum while on the 
probiotic and while on the 
placebo.in KZN Durban  
Sputum analysis 
reports  
Repeated ANOVA analysis 
Descriptive statistics for 
change in sputum score 
To determine and compare the 
number of episodes of symptoms 
(coughing, wheezing, thrush, 
diarrhea, constipation, vomiting, 
stomach ache, fever, runny nose, 
sore throat and ear ache) while on 
the probiotic and while on the 
placebo in KZN Durban 








The primary purpose of the study was to determine whether supplementation with a 
probiotic (L. reuteri) would improve anthropometric measurements, reduce the incidence 
and shorten the duration of lung infections and would maintain or prevent deterioration in 
lung function in CF patients Kwazulu-Natal (KZN) attending the CF clinics in Durban.  
The secondary purpose of the study was to compare the nutritional status at the end of the 
study of CF patients attending CF clinics in KZN Durban with CF patients attending CF 
clinics in Cape Town from the published data by Westwood & Saitowitz (1999).  Data 
reported from the Durban study included weights, heights, MAC, TSF, lung functions, 
sputum analysis, a food frequency questionnaire to assess whether the CF patient was 
consuming other probiotics and a symptom diary recording the incidence of eleven 
different symptoms.   
 
4.1 SAMPLE CHARACTERISTICS DURBAN STUDY  
 
Twenty three patients started the study.  Of these 1 withdrew after the first month having 
claimed that the probiotic gave him diarrhoea.  Five patients were excluded at the 6 
month crossover as they did not return either their straws or their symptom diary.  The 
reasons are listed in Table 8.  One was excluded at the end of probiotic of the study as 
they did not attend the last clinic for their final measurements.  A total of 16 patients 
completed the study, 8 were in group A that received the probiotic first and then the 









Table 8  Reasons for not returning straws  
‘left straws in Durban when going back to Cape Town for last 6 months’  
‘straws & symptom diary got lost while moving house’   
‘Maid threw straws and symptom diary away’ 
‘straws and symptom diary got lost’ 
‘left them at home’ 
 
As the final sample sizes were small the exclusions could have affected randomization 
therefore baseline data was checked for incomplete randomization.  Since at baseline 
there were no significant differences in mean age, proportion of males and females, 
anthropometry, lung function measurements and mean sputum scores between the 2 
groups, the groups were comparable.  Any changes which occurred over time therefore 
could be attributed to the treatment received rather than to baseline differences.  
 
In addition to the small sample size there was a large degree of non compliance both with 
taking the straws and with keeping the symptom diary.  Patients were required to take 
360 straws over the 12 month study period (1 per day).  Table 9 shows the compliance 
rate in each 6 month period.  Sixty nine percent of the group took under 75 % of the 
required number of straws for the study period for the first 6 month period.  This 
improved slightly for the second period dropping to 56 %.   
 
There was no difference between the proportions of compliant participants per group in 
either of the 6 month periods (Fisher’s exact p=1.000).  Because non compliance was the 
same in each group, an intention to treat analysis was subsequently used5.  Across the 




                                                 
5 The rationale for an intention to treat analysis analyses placebo and treatment groups as per initial 
allocation regardless of compliance levels in the treatment groups. 
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Table 9  Compliance rate of straw use 
Number of straws 
used 
Compliance rate 
First 6 months 
n=16 
Second 6 months 
n=16 
0-90 0 to 50 % 7 4 
91 to 135 50 to 74% 4 5 
136 to 161 75 to 89% 2 4 
162 to 180 90% to 100% 3 3 
 
Most of the adult patients mentioned that by using the straw they did not feel like they 
were taking medication and that they would have preferred to have taken a tablet which 
they perceived to be more efficient. 
 
4.1.1 Age and Gender 
 
All participants in the study were of Caucasian origin.  As there was a wide range in age 
for this study (8 to 31 years) the age groups were divided into non-adolescents which 
were 6 to 12.99 years old (n=4), adolescents from 13 to 19.99 years of age (n=8) and 
adults ≥ 20 years (n=4).  The study ran for 12 months and 2 male subjects moved from 
the under 19.99 years to the ≥ 20 year old group after the first six months.  The groups 
were further divided into those 6 to 9.99 years of age (n=2), 10 to 12.99 years (n=2), 13 
to 19.99 years (n=8) and ≥ 20 years of age (n=4).  These age divisions were done so that 
the data could be compared to other studies that had looked at the ≤ 9.99 year olds and 
the adolescence years.  The mean age was 17.5 years (SD 6.4 range 8-31).  The majority 
(n=6) were adolescents (Table 10), 4 were ≤12.99 years and 6 were ≥ 20 years.  There 








Table 10  The age and gender distribution of the patients who completed the study 
Age group No. of patients No. of Males No. of Females 
6 to 9.99 years 
Non-adolescent  
2 1 1 
10 to 12.99 years 
Non-adolescent 
2 1 1 
13 to 19.99 years 
Adolescent  
6 2 4 
≥ 20 years 6 5 1 
Total 16 9 7 
 
4.1.2 Shwachman Score 
 
The Shwachman score was used to measure the severity of lung disease.  The 
questionnaire consists of four sections, each with a rating from 0-25.  The four sections 
included are general activity, physical examination, nutrition and chest x-ray.  A score of 
86-100 is excellent, 71-85 is good, 56-70 is mild, 41 -55 is moderate and 0-40 indicates 
severe lung disease.  The mean score for the group was 71.06 (SD 15.24 range 41 to 90).  
Two patients scored in the moderate range, 6 in the mild range, 4 in the good range and 4 
in the excellent range.   
 
4.2      WEIGHT 
 
The mean weight at baseline (which was 6 months before they took the probiotic) was 
45.3 kg (Table 11).  On starting the probiotic 6 months later6 the mean weight was 47.3 
kg which was an increase of 2 kg.  Six months after that at the end of probiotic it was 
48.5 kg which was an increase of 1.2 kg.  This was a total weight gain of 3.2 kg across 
the 12 month period which was significant (p=0.010).  The expected weight gain over a 
                                                 
6 Weights for the placebo group were the weights six months before start of probiotic ie when off probiotic. 
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six month time period would have been between 1.5 to 3 kg readings off the CDC 2000 
growth charts.   
 
There was a significant difference in the weight at baseline compared to end of placebo 
(p=0.006) but no difference in weight at the start of the probiotic compared to the end 
probiotic (p=0.166).  This meant that there was a lower weight gain while on probiotic.  
Statistically however there was no significant difference between the treatment groups for 
weight gain (p=0.304).  See summary Table 12. 
 
There was a non significant gain in weight in all age groups over the 12 months period.  
The 13 to 19.99 year olds were the only group to non significantly increase their weight 
more on the probiotic versus off the probiotic.  However the amount of weight gained off 
probiotic was not significantly different to the amount of weight gained on probiotic for 
all age groups except the ≥ 20 years who significantly lost weight while on the probiotic 


















Table 12  Summary of weight changes across the study 
Comparison of weight change from start to end of the study 
 Group in total 
≤ 9.99 
years 
10 to 12.99 
years 




















Males > NS 





Females > S 
(p=0.041) > ? S > ? S 
> NS 
(p=0.200) > ? S 
Comparison of weight change on probiotic with weight change off probiotic 
 Group in total 
≤9.99 
years 
10 to 12.99 
years 
















(p=0.412) <? S 








(p=0.592) <? S > ? S 
<NS 
(p=0.921) <? S 
>  increase   < decrease   S  significant   NS  non-significant   ? S Query Sig (n=1)   wht weight 
 
 
The mean weight of the males at baseline was 49.6 kg (Table 13).  Their weight before 
starting the probiotic was 51.6 kg which was an increase of 2 kg.  At the end of the 
probiotic, six months later it was 52.4 kg which was an increase of 0.8 kg.  This was a 
total weight gain of 2.8 kg across the 12 month period which was not significant 
(p=0.114).  Although they appeared to gain more weight off probiotic this finding was 
not significant (p=0.412) possibly due to the small sample size.  There was an 
improvement in weight among the males in all the age groups however as (n=1) in some 
of the groups significance could not be calculated.  There was no significant difference in 
weight gain whether on or off probiotic in all age groups except for the ≥ 20 year olds 
males (p=0.027) who significantly lost weight.  In addition one male subject in the 10 




The mean weight of the females at baseline was 39.8 kg (Table 14).  Their weight before 
the start of probiotic was 41.8 kg which was an increase of 2.0 kg.  At the end of 
probiotic it was 43.3 kg which was a weight increase of 1.5 kg.  This was a total weight 
gain of 3.5 kg across the 12 month period which was significant (p=0.041).  Although 
they appeared to gain slightly more weight off probiotic the finding was not significant 
(p=0.592).  There was an increase in weight among the females in all age groups except 
the ≥ 20 year olds who lost weight while on probiotic however as n=1 in some of the 
groups significance could not be calculated (Table 12, Table 14).  The 10 to 12.99 age 
group was the only age group to gain a non significant amount of weight on the probiotic.  
There was no significant difference in weight gain in females in all age groups when on 
or off probiotic (p=0.592). 
 
The males gained 2.8 kg compared to the females 3.5 kg over the 12 months which was 
not significant (p=0.377).   
 
The CDC tables for WFA were used to calculate the percentiles of those ≤ 20 years 
(Table 15, Figure 9, and Figure 10).   
 
When considering the patients individually, at baseline 3 males and 3 females were below 
the 3rd percentile and therefore wasted.  Of these one was 10 years, one was 13 years, 
three were 14 years and one was 20 years old.  At the end of the probiotic 2 males and 3 
females were below the 3rd percentile.  The 20 year old male had managed to gain weight 










Table 15  Weight for age percentiles for those less than and equal to 20 years by gender 
at baseline, start of probiotic and end of probiotic 













On and below 95th 1 0 0 0 0 0 
On and below 90th  0 1 1 1 0 0 
On and below 75th  0 0 0 0 1 1 
On and below 50th  0 0 0 1 2 2 
On and below 25th  1 1 2 1 0 0 
On and below 10th  1 1 1 0 0 0 
On and below 5th   0 0 2 0 0 1 








Figure 10  Weight for age percentiles for six females at baseline, start of probiotic and 
end of probiotic 
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The weight data was also analysed using the following indictors:  Weight for age (WFA) 
Z-scores (Table 16) and %EWFA (Table 17).  Although the WFA Z scores seemed to 
improve slightly off probiotic and regress while on probiotic this change was very small 
and not significant (p=0.742).  There was no significant difference between the treatment 
groups in %EWFA (p=0.765).  Weight for age, %EWFA and WFA Z scores all followed 
a similar trend to all the other weight categories that have been discussed.    
 
4.3       HEIGHT 
 
The mean height was 156.22 cm at baseline, 158.14 cm at the start of probiotic and 
160.17 cm at the end of probiotic (Table 18).  The mean heights improved significantly 
from the baseline to the end of the study by 3.95 cm (p=0.001).  There was no difference 
in their increase in height whether they were off probiotic or on probiotic (p=0.838). 
 
When looking at the increase height over the year by age group the only group to reach 
significance was the 13 to 19.99 year olds (p=0.006) (Table 18).  The height for the ≥20 
year olds remained the same over the year.  While on probiotic the group as a whole, the 
9.99 years olds and the 13 to 19.99 year olds increased more in stature than off probiotic 
but this did not reach significance (Table 19). 
 
The mean height of the males at the beginning of the study was 160.94 cm, at the start of 
probiotic was 162.82 cm and at the end of probiotic was 164.47 cm (Table 20).  From six 
months before the start of the probiotic to the end of probiotic the males height increased 
significantly by 3.3 cm (p=0.010).  The mean height gained for males in the group off 
probiotic was 1.90 cm and on probiotic was 1.66 cm.  There was no significant difference 
in their increase in height whether they were off probiotic or on probiotic for each age 
group (Table 19).  The male aged 10 to 12.99 years, was the only group to increase their 
height more while on probiotic than off probiotic but the difference was not significant 




Table 19  Summary of height changes across the study 
Comparison of change in height from start to end of the study 
 Group in total 
≤ 9.99 
years 
10 to 12.99 
years 





















Males > S 






Females > S 





Comparison of change in height on probiotic with height change off probiotic 
 Group in total 
≤ 9.99 
years 
10 to 12.99 
years 





















Females > NS 






















The mean height of the females at the beginning of the study was 150.17 cm, at the start 
of probiotic was 152.14 cm and at the end of probiotic was 154.63 cm (Table 21).  The 
females height increased significantly by 4.46 cm (p=0.022) (Table 21).  There was a non 
significant increase in height in all age groups except for the ≥ 20 year olds whose height 
remained the same.  Although the females appeared to grow 1.13 cm more than the males 
the difference was non significant (p=0.549).   
 
The mean height gained for females off probiotic was 1.97 cm and on probiotic was 2.49 
cm.  This was a non significant finding of p=0.577.  All age groups appeared to grow 
more while on probiotic except the 10 to 12.99 year olds (Table 19) although the findings 
were non significant. 
 
On average the males were 10.77 cm taller than the females six months before the start of 
the probiotic and 9.64 cm taller at the end of probiotic.  This difference was not 
significant (p=0.295).   
 
The CDC tables for HFA were used to calculate the percentiles of those ≤ 20 years (Table 
22, Figure 11, Figure 12)7.   
 
When looking at the data on an individual basis, three boys (13, 14 and 20 years) were 
under the 5th percentile for height six months before start of probiotic.  Two remained 
below the 5th and the 20 year old improved to below the 25th percentile by the end of 
probiotic.  Two girls (9 ½ and 14 years) were below the 5th percentile six months before 







                                                 
7 CDC tables range from 2 to 20 years 
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Table 22  Height for age percentiles for those less than and equal to 20 years by gender at 
baseline, start of probiotic and end of probiotic 













On and below 90th  0 0 0 0 0 0 
On and below 75th  1 2 2 1 2 3 
On and below 50th  1 0 0 2 1 0 
On and below 25th  0 0 1 1 1 1 
On and below 10th  1 1 1 0 0 0 



















Figure 12  Height for age percentiles for six females six months before start of probiotic, 
start of probiotic and end of probiotic 
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Summary data for Z-scores for HFA can be seen in Table 23.  There was no significant 
difference in the Z-scores HFA for the group as a whole, whether off probiotic or on 
probiotic for both males (p=0.989) and females (p=0.460).  Summary data for percentage 
expected height for age can be seen in Table 24.  There was no significant difference 
between the treatment groups (p=0.254).   
 
Midarm circumference and TSF measurements were not taken at the crossover point of 
the study but only at the start and end of the study.  The readings have been shown in 
Appendix L.  The measurements were used to compare with the published data of 
Westwood & Saitowitz (1999). 
 
4.4 COMPARISON OF ANTHROPOMETRIC STATUS OF CYSTIC FIBROSIS 
PATIENTS IN DURBAN AND CAPE TOWN 
 
Anthropometric data namely weight, height, MAC and TSF measurements were collected 
to compare the nutritional status of CF patients attending the 2 KZN Durban clinics to 
that of the CF patients attending the Cape Town clinics.  Westwood & Saitowitz (1999) 
used a modification of the Waterlow and Rutishauser classification for growth 
measurements (Ramsey et al (1992) based on percentage expected weight for height (% 
EWFH) the Durban data was converted to %EWFH to enable the comparison (Table 25).  
Only 50% of the Durban patients had a normal %EWFH versus 62.2% of the Red Cross 
patents.  A higher percentage of the Durban patients (50%) were suffering from 
underweight/mild malnutrition versus the Red Cross patients (32.4%).  At the Red Cross 
clinic however 13.5% suffered from either severe or moderate malnutrition which was 
slightly higher than the 12.5% moderate malnutrition found in the Durban clinics where 





Table 25  Comparison of the percentage expected weight for height at the end of the 
study of the Durban Clinics (2005) to those attending the CF clinic at Red Cross Hospital 
in 1996 (Westwood & Saitowitz 1999)  





%EWFH >110% (overweight) 5.4 0.0 
%EWFH 90-110% (normal) 62.2 50.0 
%EWFH 85-89% (underweight) 5.4 18.8 
%EWFH 80-84% (mild malnutrition) 13.5 18.8 
%EWFH 75-79% (moderate malnutrition) 5.4 12.5 
%EWFH < 75% (severe malnutrition) 8.1 0.0 
MAC < 5th percentile 38.1 56 
TSF < 5th percentile 28.6 38 
 
Fifty six percent of the study group was below the 5th percentile for MAC readings at the 
end of the study (Appendix L).  These figures are much higher than the Cape Town 
(n=21) who had only 38 % below the 5th percentile.   
 
Thirty eight percent of the study population in Durban had TSF below the 5th percentile 
compared to 29% of the Cape Town clinic (n=21).   
 
4.5       INCIDENCE AND DURATION OF LUNG INFECTION 
 
Incidence rate was defined as the number of new episodes of lung infection divided by 
person-months at risk.  Person-month at risk was calculated using the number of persons 
(n=16) multiplied by the number of months (n=6).  While on probiotic there were 38 
infections in total out of 96 person-months at risk (Table 26).  This is an incidence rate of 
39.6 per 100 person-months (95 % CI 27.0 to 51.2).  While off probiotic there were 28 
lung infections in total out of the 96 month period, resulting in an incidence rate of 29.2 
per 100 person-months (95% CI 18.4 to 39.9) (Table 26).  
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Table 26  Episodes of lung infections by treatment group 
No of infections Probiotic Jan to June (n=8) Placebo July to Dec (n=8) 
Group A  24 13 
 Probiotic July to Dec Placebo Jan to June 
Group B  14 15 
Sum 38 28 
 
The number of lung infections while off probiotic and probiotic was compared using both 
relative risk and repeated measures of ANOVA.  The relative risk (exposed relative to 
unexposed) was 1.36 (95 % CI 0.83 to 2.21). This indicates that those exposed to the 
probiotic were at a 1.36 times higher risk of having a lung infection than those not 
exposed. However as the 95 % CI crossed over the null value of 1 the relative risk was 
not significantly greater than 1 at the 95 % level.  The p value was 0.134, confirming that 
there was no significant association between the exposure to probiotic and an increase in 
lung infection rate.   
 
Using the repeated measure of ANOVA there were no significant differences in the 
outcome of number of infections. There was no significant differences between the 
groups over each 6 month period (p=0.184). However, there was a trend for probiotic 
showing a reduction in the mean number of infections when on the placebo first 
compared with in the group which received the probiotic first (Figure 13). The group that 
received the placebo first remained relatively constant with mean number of infections 


























Number of lung infections
 
Figure 13  Profile plot of mean number of lung infections per treatment group  
 
The duration on antibiotics was taken as a proxy measure for duration of lung infection.  
The total duration of days on antibiotics while taking the probiotic was 1828 days. This is 
a mean of 121.9 days per participant (SD 75.9) (Table 27).  The mean duration on 
antibiotics while taking the placebo was 1488 days (Table 27). This was a mean of 99.2 
days per person (SD 81.9). There was no significant difference between the group on or 








Table 27  Duration on antibiotics by treatment group 
No of days on 
antibiotics 
Probiotic Jan to June (n=8) Placebo July to Dec (n=7) 
Group A  939 320 
 Probiotic July to Dec 
(n=7) 
Placebo Jan to June 
(n=8) 
Group B  889 1168 
Sum 1828 1488 
 
There was a significant decrease in the use of antibiotics during the first 6 months (939 + 
1168= 2107) of the year compared to the second 6 months (320+889=1209) (p=0.046) 
regardless of treatment (p=0.440).  Both groups therefore decreased over time with regard 
to mean duration of antibiotics from the first 6 months to the second 6 months.  This was 
not related to the treatment as the sequence of treatments cancelled this decrease out 
(Figure 14).  Although more antibiotics were used in the first 6 months of the study there 



























Figure 14  Profile plot of mean duration of antibiotics per treatment group 
 
4.6       LUNG FUNCTION 
 
FORCED EXPIRATORY VOLUME IN ONE SECOND 
 
The sum of the total percentage change in FEV1 while on the probiotic was 30%.  This 
was a mean increase of 1.9% (Table 28).  The sum of the total percentage change in 






Table 28  Percentage change in Forced Expiratory Volume in one second for the 
treatment groups  
Percentage change in 
FEV1 
Probiotic Jan to June (n=8) Placebo July to Dec (n=8) 
Group A  17 -50 
 Probiotic July to Dec (n=8) Placebo Jan to June (n=8) 
Group B  13 -15 
Sum 30 -65 
 
There was a marginally non-significant treatment effect for FEV1 (p=0.079).  Both groups 
showed higher mean FEV1 scores on the probiotic than on the placebo. Thus, while there 
was a trend in favour of the probiotic displayed for FEV1 improvement, this could not be 
proved conclusively due to the non significant p value.  Figure 15 shows the mean FEV1 




























Figure 15  Profile plot of Forced Expiratory Volume in one second per treatment group 
 
FORCED VITAL CAPACITY  
 
The sum of the total percentage change in FVC while on the probiotic was 41%.  This 
was a mean increase of 2.6 % (Table 29).  The sum of the total percentage change in FVC 
while on the placebo was a decrease of -60%.  This was a mean decrease of -3.75 % 








Table 29  Percentage change in Forced Vital Capacity readings for the treatment groups  
Percentage Change 
in FVC 
Probiotic Jan to June (n=8) Placebo July to Dec (n=8) 
Group A  20 -40 
 Probiotic July to Dec (n=8) Placebo Jan to June (n=8) 
Group B  21 -20 
Sum 41 -60 
 
The repeated measures ANOVA analysis for FEV1 and FVC involved calculating the 
difference between end of probiotic of the first and end of probiotic of the second period 
values whilst controlling for starting values which were used as a covariate in the model.  
 
The same trend of probiotic is evident with FVC.  There was a marginally non significant 
treatment effect (p=0.094) which was favorable towards the probiotic rather than the 


























Figure 16  Profile plot of Forced Vital Capacity per treatment group 
 
4.7       SPUTUM ANALYSIS 
 
A total of 3 patients of the six from January to June and of the five from July to 
December did not culture P. aeruginosa during the 12 month study.  Table 30 shows the 
figures for culturing P. aeruginosa from January to December.   
 
Table 30  Pseudomonas aeruginosa culture figures 
 Jan - June July - Dec 
Number of patients not culturing P. aeruginosa 6 (38%) 5 (32%) 
Number of patients culturing P. aeruginosa 10 (62%) 11 (69%) 
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Of the common bacteria found in CF patients (Hart & Winstanley 2002) the three most 
troublesome pathogens were chosen (West et al 2002).  These were P. aeruginosa (dry 
and muciod), S. aurens, and B. cepacia. Sputum score at start of probiotic (first period) 
and end of probiotic (second period) was calculated as the sum of responses (on a scale of 
0 to 4) to the three selected bacteria. The sputum score while off probiotic was calculated 
in the same way.  The higher the score, the more bacteria present. Change in sputum 
score was used as a measure of the change in bacterial infection during each period.  
 
The total change in sputum score while on the probiotic was -5 (Table 31). This is a mean 
change of -0.38 indicating that the probiotic showed a mean decrease in sputum score.  
The total change in sputum score while on the placebo was 12 indicating a mean increase 
of 1.0 (Table 31).  
 
Table 31  Change in sputum score by treatment group 
Change in sputum 
score 
Probiotic Jan to June (n=8) Placebo July to Dec (n=8) 
Group A  -1 0.0 
 Probiotic July to Dec (n=5) Placebo Jan to June (n=5) 
Group B  -4 12 
Sum -5 12 
 
Although there was a trend indicating that the probiotic resulted in slightly lower mean 
scores of bacteria in the sputum than the placebo, especially in the group that took the 
placebo first, this trend was not significant (p=0.453).  Figure 17 shows the mean sputum 

























Figure 17  Profile plot of mean sputum score per treatment group 
 
4.8       SYMPTOMS 
 
Of the 16 participants only 8 subjects filled in the symptom diaries for both periods.  
Fever, runny nose, sore throat and ear ache where grouped together as they are similar 
conditions.  The total number of symptoms was calculated on and off the probiotic (Table 
32).  There was no significant difference in the incidence of coughing, wheezing, thrush, 
diarrhea, constipation, vomiting and stomach ache when on or off the probiotic.  There 
was a significantly higher mean number of episodes of fever, runny nose, sore throat and 





Table 32  Mean episodes of symptoms  
Mean episodes of symptoms  Probiotic Placebo 
All Symptoms Descriptive stats Mean (n=11) 128.27 156.18 
  SD 117.73 148.33 
  Min  16 0 
  Max 299 499 
 Paired t-test (n=8) Mean (n=8) 157.38 127.63 
  SD 126.75 112.31 
  Std. error mean 44.81 39.71 
  p value (2-tailed) 0.148 
Mean episodes of symptoms  Probiotic Placebo 
Descriptive stats Mean (n=11) 23.73 19.91 
 SD 20.39 23.91 
 Min  0 0 
Fever, runny 
nose, sore 
throat & ear 
ache 
 Max 66 82 
 Paired t-test (n=8) Mean (n=8) 28.00 10.38 
  SD 21.94 11.17 
  Std. error mean 7.76 3.95 
  p value (2-tailed) 0.016 
Mean episodes of symptoms  Probiotic Placebo  
Wheeze Descriptive stats Mean (n=11) 14.27 30.64 
  SD 31.11 46.69 
  Min  0 0 
  Max 105 159 
 Paired t-test (n=8) Mean (n=8) 17.75 15.25 
  SD 36.30 20.79 
  Std. error mean 12.94 7.35 

















Table 32  Mean episodes of symptoms continued 
Mean episodes of symptoms  Probiotic Placebo 
Cough Descriptive stats Mean (n=11) 62.09 83.36 
  SD 57.84 90.69 
  Min  4 0 
  Max 168 255 
 Paired t-test (n=8) Mean (n=8) 74.88 72.75 
  SD 63.19 82.89 
  Std. error mean 22.34 29.31 
  p value (2-tailed) 0.888 
Mean episodes of symptoms  Probiotic Placebo 
Thrush Descriptive stats Mean (n=11) 4 2.73 
  SD 12.62 8.08 
  Min  0 0 
  Max 42 27 
 Paired t-test (n=8) Mean (n=8) 5.50 3.63 
  SD 14.77 9.47 
  Std. error mean 5.22 3.35 
  p value (2-tailed) 0.360 
Mean episodes of symptoms  Probiotic Placebo 
Diarrhea Descriptive stats Mean (n=11) 2.18 2.18 
  SD 3.92 5.08 
  Min  0 0 
  Max 10 17 
 Paired t-test (n=8) Mean (n=8) 1.75 2.63 
  SD 3.41 5.98 
  Std. error mean 1.21 2.11 
  p value (2-tailed) 0.682 
Mean episodes of symptoms  Probiotic Placebo 
Constipation Descriptive stats Mean (n=11) 0.45 0.18 
  SD 1.51 0.60 
  Min  0 0 
  Max 5 2 
 Paired t-test (n=8) Mean (n=8) 0.63 0.25 
  SD 1.77 0.71 
  Std. error mean 0.63 0.25 








Table 32  Mean episodes of symptoms continued 
Mean episodes of symptoms  Probiotic Placebo 
Vomiting Descriptive stats Mean (n=11) 1.55 0.3 (n=10) 
  SD 2.21 0.95 
  Min  0 0 
  Max 7 3 
 Paired t-test (n=8) Mean (n=8) 1.88 0.00 
  SD 2.48 0.00 
  Std. error mean 0.88 0.00 
  p value (2-tailed) 0.069 
Mean episodes of symptoms  Probiotic Placebo 
Stomach ache Descriptive stats Mean (n=11) 20.00 18.60 (n=10) 
  SD 33.49 31.15 
  Min  0 0 
  Max 92 89 
 Paired t-test (n=8) Mean (n=8) 27.00 22.75 
  SD 37.35 33.89 
  Std. error mean 13.21 11.98 
  p value (2-tailed) 0.372 
 
4.9   FOOD FREQUENCY QUESTIONAIRE REGUARDING PRE AND PROBIOTIC 
USE 
 
Forty four percent of the CF patients did not take any food supplements.  Of the 56 % 
who did take a food supplement, the most commonly used was Nutren Activ (25%), 
Nesquik (12.5%), Ensure (6.25%) and others (12.5%).  How often they were used ranged 
from once or twice a week (n=1), once a day (n=4), twice a day (n=2) and three times a 
day (n=1) and other (n=1).  When mixing the supplements, 5 made it up according to 
directions; one made it weaker and 3 made it stronger than directed.  Nutren Activ was 
the only commercial product being used that currently contains a prebiotic.   
 
In an attempt to ensure that the patients were not receiving additional probiotics from 
other sources they were asked about their consumption of yoghurt and other products that 
may contain a probiotic.  Yoghurt was consumed by 81% of which 25% were brand 
specific.  These brands included Danone, Nutriday and Fairfields.  Frequency of use 
ranged from once in 2 months (n=1), once or twice a month (n=2), once or twice a week 
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(n=7) or once a day (n=3).  None of the brands mentioned contained a live culture with a 
known effect. 
 
4.10      SUMMARY OF RESULTS 
 
Table 33 shows the summary of the anthropometric data for the period prior to starting 
probiotic (while off probiotic) and while on the probiotic.  While off probiotic there was 
more weight gained, a better increase in %EWFA, Z score (weight for age) Z score 
(height for age), % EHFA, %EWFH, BMI for ≤ 20 years and BMI Z score.  % Expected 
weight for age and height were both better on probiotic.  All the measurement were non 
significant.  Table 34 shows the summary of all other results during the probiotic period 
and off probiotic period.   
 
Table 33  Summary of changes in anthropometry during period prior to probiotic 
consumption and during probiotic consumption. 










+ 2 kg + 1.2 kg 0.304 
Z  score (weight-for-age) 
for patients ≤ 20 years 
+ 0.03 - 0.05 0.742 
% Expected weight for age 
for patients ≤ 20 years 
+ 0.4 % + 2.0 % 0.765 
Height (cm) 
 
+1.93cm +2.03cm 0.838 
Z  score (height-for-age) 
for patients ≤ 20 years 
+ 0.03 - 0.02 0.783 
% Expected height for age  
for patients ≤ 20 years of age 
+ 0.8 % + 0.3 % 0.254 
% Expected weight for height  
for patients ≤ 20 years of age 
+ 2.2 % + 0.3 % 0.448 
Body Mass Index of adults (kg/m2) (≥ 
20 years) 
0.6 kg/m2 -0.1 kg/m2 0.411 
Body Mass Index of children 
(kg/m2) (for ≤ 20 year olds) 
0.4 kg/m2 0.02 kg/m2 0.651 
Z score (Body Mass Index for age) of 
children (for ≤ 20 year olds) 
+ 0.09 - 0.09 0.272 
*  Changes are for the whole group unless otherwise indicated 
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The number of lung infections was less off probiotic and less number of days on 
antibiotics.  The FEV1 and FVC, a lower microbiological sputum score and less episodes 
of all symptoms seemed to improve while on the probiotic.  Again all measurements were 
non significant (Table 34).   
 
Table 34  Summary of changes in lung infections, function, sputum and symptoms while 
on and off probiotic 
 
 Off Probiotic On Probiotic p value 
Number of lung infections 28 38 0.134 
Duration on antibiotic (days) 1488 1828  
Forced expiratory volume in 
one second (% change) 
-65 30 0.079 
Forced vital capacity (% 
change) 
-60 41 0.094 
Change in sputum score  12 -5 0.453 
Mean episodes of all 
symptoms 
156.18 128.27 0.148 
Fever, runny nose, sore throat, 
& ear ache 
19.91 23.73 0.016 
Wheeze 30.64 14.27 0.776 
Cough 83.36 62.09 0.888 
Thrush 2.73 4 0.360 
Diarrhoea 2.18 2.18 0.682 
Constipation 0.18 0.45 0.351 
Vomiting 0.3 1.55 0.069 
Stomach ache 18.60 20.00 0.372 
 
 













to end of 
study 
Change in 
weight 6 months 
on placebo 
Change in 
weight 6 months 
on probiotic 
p value for 
placebo vs 
probiotic 
Mean 21.7 Mean 22.9 Mean 23.9 Mean 1.2 Mean 0.6 
SD 0.99 SD 0.99 SD 0.14 SD 0.00 SD 0.28 
6 to 9.99 years 
(n=2) 
Range 21.0 – 22.4 Range 22.2 – 23.6 Range 23.8 – 24.0 
0.170 
Range 1.2- 1.2 Range 0.4 – 0.8 
0.205 
Mean 29.9 Mean 33.4 Mean 35.9 Mean 3.5 Mean 2.5 
SD 5.81 SD 6.22 SD 10.11 SD 0.42 SD 3.89 
10 to 12.99 
years (n=2) 
Range 25.8 – 34.0 Range 29.0 – 37.8 Range 28.7 – 43.0 
0.300 
Range 3.2 – 3.8 Range -0.3 – 5.2 
0.742 
Mean 50.1 Mean 51.3 Mean 53.7 Mean 1.2 Mean 2.4 
SD 19.37 SD 16.83 SD 15.96 SD 2.88 SD 3.07 
Range 30.0 – 89.0 Range 35.0 – 85.4 Range 37.3 – 84.0 Range -3.6 – 5.0 Range -1.4 – 8.7 
13 to 19.99 
years 




Mean 55.3 Mean 58.4 Mean 56.75 Mean 3.3 Mean -1.85 
SD 7.82 SD 8.61 SD 8.45 SD 2.62 SD 1.39 
Range 43.9 – 61.8 Range 46.5 – 65.0 Range 45.9 – 64.0 Range 0.30 -6.70 Range -3.70 - -0.5 
≥20 years 




Mean 45.3 Mean 47.3 Mean 48.5 Mean 2.0 Mean 1.2 
SD 18.28 SD 17.23 SD 16.57 SD 2.53 SD 3.04 
Group as a 
whole (n=16) 
Range 21.0 – 89.0 Range 22.20 – 85.4 Range 23.80 – 84.0 
0.010 
Range -3.60 – 6.7 Range -3.7 – 8.7 
0.304 
 
Table 13  Weights for males by age group six months before start of probiotic, start of probiotic and end of probiotic. 
Age group 









p value  
from start 










p value for 
placebo vs 
probiotic 
6 to 9.99 years 
(n=1*) 
Mean 21.0 Mean 22.2 Mean 23.8  Mean 1.2 Mean 0.8  
10 to 12.99 years 
(n=1*) 
Mean 25.8 Mean 29.0 Mean 28.7  Mean 3.2 Mean -0.3  
Mean 55.5 Mean 56.4 Mean 59.8 Mean 0.9 Mean 3.3 
SD 23.71 SD 21.07 SD 18.91 SD 3.04 SD 4.14 
Range 33.2 – 89.0 Range 35.0 – 85.4 Range 37.9 – 84.0 Range -3.6 – 2.9 Range -1.4 – 8.7 
13 to 19.99 years 




Mean 59.1 Mean 62.5 Mean 60.4 Mean 3.4 Mean -2.1 
SD 2.33 SD 3.91 SD 5.31 SD 3.4 SD -2.1 
Range 57.7 – 61.8 Range 58.0 – 65.0 Range 54.3 – 64.0 Range 0.3 – 6.70 Range -3.7 - -0.5 
≥20 years 




Mean 49.6 Mean 51.6 Mean 52.4 Mean 2.0 Mean 0.8 
SD 20.89 SD 19.95 SD 19.11 SD 2.76 SD 3.68 
Groups as a 
whole (n=9) 
Range 21.0 – 89.0 Range 22.2 – 85.4 Range 23.8 – 84.0 
0.114 
Range -3.60 – 6.7 Range -3.7 – 8.7 
0.412 
*n=1 significance could not be calculated 
 
 
Table 14  Weights for females by age group six months before probiotic, start of probiotic and end of probiotic 
Age group 



























6 to 9.99 years 
(n=1 *) 
Mean 22.4 Mean 23.6 Mean 24.0  Mean 1.2 Mean 0.4  
10 to 12.99 years 
(n=1*) 
Mean 34.0 Mean 37.8 Mean 43.0  Mean 3.8 Mean 5.2  
Mean 44.6 Mean 46.2 Mean 47.6 Mean 1.6 Mean 1.4 
SD 15.30 SD 12.20 SD 11.73 SD 3.14 SD 1.54 
13 to 19.99 years 
(n=4) 
Range 30.0 – 64.6 Range 35.0 – 61.8 Range 37.3 – 63.6 
0.200 
Range -2.6 – 5.0 Range -0.8 – 2.6 
0.921 
≥ 20 years 
(n=1*) 
Mean 43.9 Mean 47.0 Mean 45.9  Mean 3.1 Mean -1.1  
Mean 39.8 Mean 41.8 Mean 43.3 Mean 2.0 Mean 1.5 
SD 13.83 SD 12.19 SD 12.02 SD 2.43 SD 2.19 
Group as a 
whole 
(n=7) Range 22.4 - 64.6 Range 23.6 – 61.8 Range 24.0 -63.6 
0.041 
Range -2.6 - 5 Range -1.1 – 5.2 
0.592 






Table 18  Heights by age group six months before start of probiotic, start of probiotic and end of probiotic 
Age group 
Height (cm) 6 months 
before probiotic 
Start of probiotic 
height (cm) 








height 6 months 
on placebo 
Change in height 







Mean 120.50 Mean 123.45 Mean 126.50 Mean 2.95 Mean 3.05 
SD 4.95 SD 4.74 SD 4.95 SD 0.21 SD 0.21 
6 to 9.99 years 
(n=2) 
Range 117.00 – 124.00 Range120.10 – 126.80 Range 123.00 – 130.00 
Std 
error of 
diff is 0 Range 2.8 – 3.10 Range 2.90 – 3.20 
0.795 
Mean 143.20 Mean 146.75 Mean 149.93 Mean 3.55 Mean 3.2 
SD 6.08 SD 9.54 SD 10.00 SD 3.46 SD 0.42 
10 to 12.99 
years (n=2) 
Range 138.90 – 147.50 Range 140.00 – 153.50 Range 142.90 – 157.00 
0.249 
Range 1.10 – 6.0 Range 2.9 – 3.5 
0.897 
Mean 159.91 Mean 162.03 Mean 164.42 Mean 2.13 Mean 2.45 
SD 14.78 SD 14.18 SD 13.00 SD 1.96 SD 2.07 
Range 135.20 – 182.00 Range 139.00 – 182.30 Range 143.90 – 182.30 Range 0 – 4.9 Range 0 – 4.9 
13 to 19.99 
years 




Mean 173.20 Mean 173.41 Mean 173.50 Mean 0.23 Mean 0.08 
SD 5.95 SD 6.09 SD 6.10 SD 0.33 SD 0.15 
Range 164.50 – 178.00 Range 164.50 – 178.00 Range 164.50 – 178.00 Range 0 – 0.7 Range 0 – 0.3 
≥ 20 years 




Mean 156.22 Mean 158.14 Mean 160.17 Mean 1.93 Mean 2.03 
SD 19.75 SD 18.93 SD 17.81 SD 1.98 SD 1.86 
Group as a 
whole 
(n=16) Range 117.00 – 182.00 Range 120.10 – 182.30 Range 123.05 – 182.30 
0.001 




Table 20  Height for males in age groups six months before start of probiotic, start of probiotic and end of probiotic 
Age group 
Height (cm) 6 
months before start 
of probiotic 
Start of probiotic 
height (cm)  
End of probiotic 



















6 to 9.99 
years (n=1*) 
Mean 117.00  Mean 120.10  Mean 123.00   Mean 3.10 Mean 2.90  
10 to 12.99 
years (n=1*) 
Mean 138.90 Mean 140.00  Mean 142.90  Mean 1.10 Mean2.90  
Mean 166.03  Mean 169.01 Mean 171.23 Mean 3.00 Mean 2.23 
SD 15.33 SD 14.58  SD 13.07 SD 1.93 SD 1.77 
Range 146.60 – 182.00 Range 150.00 – 182.30 Range 153.70– 182.30 Range 0 – 4.9 Range 0 – 3.7 
13 to 19.99 
years 




Mean 176.10  Mean 176.40 Mean 176.50 Mean 0.30 Mean 0.10 
SD 1.65  SD 1.44  SD 1.320 SD 0.36 SD 0.17 
Range 175.00 – 178.00 Range 175.20 – 178.00 Range 175.50 – 178.00 Range 0 – 0.7 Range 0 – 0.3 
≥ 20 years  




Mean 160.92  Mean 162.82 Mean 164.47 Mean 1.90 Mean 1.66 
SD 22.14 SD 21.49 SD 20.37 SD 1.81 SD 1.62 
All males 
(n=9) 
Range 117.00 - 182.00 Range 120.10 – 182.30 Range 123.00 – 182.30 
0.010 
Range 0 - 4.9 Range 0 – 3.7 
0.616 
*n=1 significance could not be calculated 
 
 
Table 21  Height for females in age groups six months before start of probiotic, start of probiotic and end of probiotic 
Age group 
Height (cm) 6 
months before 
probiotic 
Start of probiotic 
height (cm) 
End of probiotic 




















6 to 9.99 years 
(n=1*) 
Mean 124.00 Mean 126.80 Mean 130.00  Mean 2.80 Mean 3.20  
10 to 12.99 
years (n=1*) 
Mean 147.50 Mean 153.50 Mean 157.00  Mean 6.00 Mean 3.50  
Mean 153.80  Mean 155.05 Mean 157.73 Mean 1.25 Mean 2.68 
SD 13.24 SD 11.54  SD 10.11 SD 1.79 SD 2.59 
13 to 19.99 
years (n=4) 
Range 135.20 – 166.50 Range 139.00 – 166.50 Range 143.90 – 167.40 
0.128 
Range 0 – 3.8 Range 0 – 4.9 
0.343 
≥ 20 years 
(n=1*) 
Mean 164.50  Mean 164.45 Mean 164.50  Mean 0 Mean 0  
Mean 150.17  Mean 152.14 Mean 154.63 Mean 1.97 Mean 2.49 
SD 15.68 SD 14.31 SD 13.26 SD 2.33 SD 2.16 
All females 
(n=7) 
Range 124.00 - 166.50 Range 126.80 – 166.50 Range 130.00 - 167.40 
0.022 
Range 0 – 6.0 Range 0 – 4.9 
0.577 









at start of the 
study 
Mean MAC at 
end of the  
study  
p value from 
start to end of 
study 
Mean TSF at 
start of the 
study  
Mean TSF at 
end of the 
study  
p value From 
start to end of 
study 
Mean 17.6 Mean 18.2 Mean 6.8 Mean 8.1 
SD 0.7 SD 0.49 SD 1.59 SD 2.65 
6 to 9.99 
years (n=2) 
Range 17.1 – 18.1 Range 17.8 – 18.5 
0.170 
Range 5.8 – 8.0 Range 6.3 – 10.0 
0.344 
Mean 18.3 Mean 20.1 Mean 7.1 Mean 7.9 
SD 1.8 SD 3.1 SD 0.53 SD 3.0 
10 to 12.99 
years (n=2) 
Range 17.0 – 19.6 Range 17.8 – 22.3 
0.317 
Range 6.8 – 7.5 Range 5.8 – 10.0 
0.742 
Mean 23.6 Mean 24.8 Mean 10.2 Mean 9.8 
SD 4.7 SD 4.2 SD 4.1 SD 4.9 
Range 18.5 – 31.7 Range 20.0 – 31.5 Range 6.3 – 19.5 Range 4.0 – 20.5 






Mean 25.1 Mean 24.6 Mean 6.4 Mean 4.7 
SD 2.6 SD 1.6 SD 4.3 SD 1.9 
Range 21.4 – 27.4 Range 22.3 – 25.1 Range 3.5 – 12.5 Range 3.3 – 7.5 





Mean 22.6 Mean 23.3 Mean 8.44 Mean 8.06 
SD 4.5 SD 4.0 SD 3.8 SD 4.2 
Group as a 
whole 
(n=16) Range 17.0 -31.7 Range 17.8 – 31.5 
0.027 







































at start the 
study 
Mean MAC at 
end of the  
study 
p value from 
start to end of 
study 
Mean TSF at 
start the 
study 
Mean TSF at 
end of the 
study  
p value  from 
start to end of 
study 
6 to 9.99 years 
(n=1*) 
Mean 17.1 Mean 17.8  Mean 5.8 Mean 6.3  
10 to 12.99 years 
(n=1*) 
Mean 17.0 Mean 17.8  Mean 6.8 Mean 5.8  
Mean 24.51 Mean 25.78 Mean 8.0 Mean 7.0 
SD 5.2 SD 4.6 SD 2.0 SD 2.4 
Range 19.5 – 31.7 Range 21.0 – 31.5 Range 6.3 – 11.0 Range 4.0 – 9.8 





Mean 26.36 Mean 25.33 Mean 4.33 Mean 3.8 
SD 1.1 SD 0.6 SD 1.4 SD 0.6 
Range 25.2 – 27.4 Range 24.9 – 26.1 Range 3.5 – 6.0 Range 3.3 – 4.5 





Mean 23.5 Mean 23.9 Mean 6.4 Mean 5.7 
SD 4.9 SD 4.4 SD 2.2 SD 2.1 
Group as a 
whole 
(n=9) Range 17.0 -31.7 Range 17.8 – 31.5 
0.408 
Range 3.5 – 11.0 Range 3.3 – 9.8 
0.047 





































at start the  
study 
Mean MAC at 
end of  the  
study  
p value from 
start to end of 
study 
Mean TSF at 
start the  
study 
Mean TSF at 
end of  the  
study  
p value form 
start to end of 
study 
6 to 9.99 
years (n=1*) 
Mean 18.1 Mean 18.5  Mean 8.0 Mean 10.0  
10 to 12.99 
years (n=1*) 
Mean 19.6 Mean 22.3  Mean 7.5 Mean 10.0  
Mean 22.75 Mean 23.83 Mean 12.4 Mean 12.6 
SD 4.75 SD 4.2 SD 4.8 SD 5.4 
13 to 19.99 
years (n=4) 
Range 18.5 – 28.5 Range 20.0 – 29.1 
0.083 
Range 9.0 – 19.5 Range 8.0 – 20.5 
0.689 
≥ 20 years 
(n=1*) 
Mean 21.4 Mean 22.3  Mean 12.5 Mean 7.5  
Mean 21.4 Mean 22.6 Mean 11.1 Mean 11.1 
SD 3.9 SD 3.6 SD 4.1 SD 4.3 
Group s a 
whole (n=7) 
Range 18.1 -28.5 Range 18.5 – 29.1 
0.015 
Range 7.5 – 19.5 Range 7.5– 20.5 
0.971 
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Figure 8  Time line showing different starts for the study for different measurements 
 
Table 16  Z scores weight for age for those 20 years and under by gender and age 
 
Z scores for 
weight for age 
Z score 6 
months before 
probiotic 
Z score  at start 
of probiotic  
Z score at end of 
probiotic 
p value for 
placebo vs 
probiotic 




Changes in Z 
score 6 months 
on probiotic 
Mean -1.09 Mean -1.08 Mean -1.13 
SD 1.28 SD 1.07 SD 0.98 
Range -3.56 to 1.36 Range -3.05 to 1.09 Range -3.63 to 0.62 
≤ 20 year olds 
n=12 n=12 n=10 
0.742 +0.01 -0.05 
Mean -1.31 Mean -1.24 Mean -1.37 
SD 1.38 SD 1.16 SD 0.91 
Range -3.56 to 1.36 Range -3.05 to 1.09 Range -3.63 to -0.68 
Males 
n=6 n=6 n=4 
0.119 +0.07 -0.13 
Mean -0.86 Mean -0.87 Mean -0.82 
SD 1.19 SD 1.00 SD 1.04 
Females 
(n=6) 
Range -2.88 to 0.80 Range -2.03 to 0.55 Range -1.93 to 0.62 
0.783 +0.01 +0.05 
Median -0.99 Median -0.95 Median -0.89 
SD 0.65 SD 0.78 SD 1.08 
Non-
adolescents  
(n=4) IQR -1.63 to -0.33 IQR -1.69 to -0.13 IQR -1.88 to 0.26 
0.951 +0.04 +0.06 
Median -0.94 Median -1.76 Median -1.58 
SD 1.55 SD 1.26 SD 1.38 
IQR -2.88 to -.020 IQR -2.03 to -0.02 IQR -1.93 to -0.24 
Adolescents  
 
n=8 n=8 n=6 
0.795 -0.82 +0.18 
The interquartile range (IQR) is the distance between the 75th percentile and the 25th percentile. The IQR is essentially the range of the middle 50% of 
the data. Because it uses the middle 50%, the IQR is not affected by outliers or extreme values. 
 










for age at start 
of probiotic  
Percentage 
expected weight 















Mean 82.6 Mean 83.0 Mean 85.0 
SD 21.32 SD 18.85 SD 18.15 
Range 57.3 – 127.0 Range 60.0 – 121.0 Range 57.0 – 119.0 
≤ 20 year olds  
n=12 n=10 n=10 
0.765 +0.4 +2.0 
Mean 81.4 Mean 80.8 Mean 83.3 
SD 25.00 SD 22.76 SD 21.04 
Range 57.3 – 127.0 Range 60.0 – 121.0 Range 57.0 -119.0 
Males 
n=6 n=4 n=4 
0.492 -0.6 +2.5 
Mean 83.7 Mean 85.3 Mean 86.7 
SD 19.27 SD 15.85 SD 16.61 
Females 
(n=6) 
Range 61.0 – 115.0 Range 69.0 – 109.0 Range 69.0 – 112.0 
0.334 +1.6 +1.4 
Mean 82.4 Mean 83.3 Mean 83.7 
SD 8.79 SD 10.01 SD 14.05 
Non adolescents 
(n=4) 
Range 72.3 – 88.0 Range 72.0 - 91.0 Range 69.0 – 97.0 
0.848 +0.9 +0.4 
Mean 78.2 Mean 79.0 Mean 80.7 
SD 20.62 SD 18.49 SD 17.99 
Range 57.3 – 115.0 Range 60.0 - 109.0 Range 57.0 – 112.0 
Adolescents 
n=8 n=6 n=6 
0.185 +0.8 +1.7 
Table 23  Z scores for height for age for those 20 years and under and by gender and age 
Z scores for 
height for age 
Z score 6 
months before 
probiotic 
Z score  at 
start of 
probiotic  
Z score at end of 
probiotic 
p value for 
placebo vs 
probiotic 








Mean -0.86 Mean -0.83 Mean -0.85 
SD 1.24 SD 1.14 SD 0.99 
Range -3.39 to 1.75 Range -3.12 to 0.94 Range -2.62 to 0.99 
≤ 20 year olds 
n=12 n=12 n=10 
0.783 +0.03 -0.02 
Mean -0.91 Mean -0.94 Mean -1.09 
SD 1.21 SD 1.02 SD 0.73 
Range -2.21 to 1.75 Range -2.42 to 0.77 Range -2.50 to 0.36 
Males 
n=6 n=6 n=4 
0.989 -0.03 -0.15 
Mean -0.80 Mean -0.69 Mean -0.54 
SD 1.38 SD 1.34 SD 1.24 
Females 
(n= 6) 
Range -3.39 to 0.68 Range -3.12 to 0.94 Range -2.62 to 0.99 
0.460 +0.11 +0.15 
Median -1.35 Median -1.37 Median -1.25 
SD 1.22 SD 1.36 SD 1.29 
Non-adolescents  
(n=4) 
IQR -1.52 to 0.68 IQR -1.26 to 0.99 IQR -1.29 to 1.02 
0.860 -0.02 +0.12 
Median -0.52 Median -0.55 Median -0.68 
SD 1.39 SD 1.43 SD 1.35 
IQR -2.21 to 0.12 IQR -2.42 to 0.44 IQR -2.50 to -0.36 
Adolescents  
n=8 n=8 n=6 
0.827 -0.03 -0.13 
The interquartile range (IQR) is the distance between the 75th percentile and the 25th percentile. The IQR is essentially the range of the middle 50% of the 














height for age 




for age at end of 
probiotic 









Mean 94.9 Mean 95.7 Mean 96.0 
SD 5.78 SD 6.03 SD 5.87 
Range 84.5 - 103.0 Range 86.0 – 103.0 Range 86.0 – 103.0 
≤ 20 year olds  
n=12 n=12 n=10 
0.254 0.8 0.3 
Mean 94.3 Mean 95.0  Mean 95.0  
SD 5.64 SD 6.19 SD 6.63 
Range 89.0 – 103.0  Range 88.0 – 103.0 Range 86.0 – 103.0 
Males 
n=6 n=6 n=4 
0.286 0.7 0 
Mean 95.8  Mean 96.5 Mean 97.0 
SD 6.39 SD 6.35 SD 5.44 
Females 
(n=6) 
 Range 84.5 - 102.0 Range 86.0 – 102.0 Range 89.0 – 102.0 
0.606 0.7 0.5 
Mean 95.33 Mean 95.67 Mean 96.00 
SD 4.16 SD 4.73 SD 5.29 
Non-adolescents  
(n=4) 
Range 92.0 - 100.0 Range92.0 – 101.0 Range 92.0 - 102.0 
Std error of diff 
is 0 0.3 0.4 
Mean 94.01 Mean 95.14 Mean 95.14 
SD 6.51 SD 6.99 SD 6.69 
Range 84.5 – 10.2.0 Range 86.0 – 10.2.0 Range 86.0 – 102.0 
Adolescents  
n=8 n=8 n=6 
0.592 1.1 0 
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CHAPTER 5:  DISCUSSION 
 
The primary aim of the study was to determine whether supplementation with a probiotic 
(L. reuteri) could be shown to stimulate the immune system, possibly reducing the 
incidence and shortening the duration of lung infections while maintaining or preventing 
deterioration in lung function in CF patients attending the CF clinics in KZN Durban.  
The secondary aim of the study was to compare the nutritional status of CF patients 
attending CF clinics in KZN Durban with CF patients attending CF clinics in Cape Town 
as compared to the published data by Westwood & Saitowitz (1999).  It was 
hypothesized that if the probiotic could stimulate the immune system and reduce the 
incidence and shorten the duration of lung infections this in turn would improve their 
anthropometric measurements.  The improved nutritional status could enhance resistance 
to lung infections interrupting the malnutrition/infection cycle and reducing mortality.  
 
5.1 STUDY COMPLIANCE 
 
Compliance was a huge issue whether measured objectively by counting straws or 
subjectively by the use of the symptom diary.  Very few patients took close to the correct 
number of straws and on average the symptom diaries were not filled in satisfactorily. 
 
In this study it was found that two 14 year olds and one 20 year old were the most 
compliant with using the straws.  This disagrees with the SA studies by Westwood & 
Saitowitz (1999) and Westwood & Ireland (2000) who showed that compliance was 
better in the younger child (under 10 years) than in the older CF patient.  Anthony et al 
(1999) stated that it was well known that adolescents and young adults are generally poor 
compliers although this was not the case in this study.   
 
In this study the parents of the more compliant children filled in the symptom diary and 
ensured that their child took the straws daily.  This agreed with Powers et al (2002) who 
noted that compliance in younger patients is directly related to the commitment of the 
primary care givers and if the mother or care giver filled in the diary more information 
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was obtained.  The Hatakka et al (2001) study had the care giver fill in the symptom 
diary as the subjects were younger (1-6 years).  This may lead to better information being 
collected as an adult care giver is more able to give an objective comment.  The study 
mentioned that they had good compliance but did not specify the compliance rate. 
 
The poor compliance during the study as a whole could be explained by the fact that the 
probiotic did not offer an immediate benefit to the patient.  Dodd & Webb (2000) found 
that if a treatment offered immediate effects then patients were more compliant.  As the 
probiotic would not be expected to have an instant response and as the adults using the 
straws had the perception of not really taking any medication this in itself would led to a 
lower compliance rate.  Compliance may have been increased if the adults had been 
given a probiotic tablet and the straws were used for the younger children only.   
 
Reasons in this study given for non compliance were similar to those found by Abbott & 
Gee (1998) and fall into the 2 categories of time and health which they found to be the 
most common reasons for non-compliance amongst CF patients.   
 
Cystic Fibrosis patients need to be compliant with enzyme therapy, daily physiotherapy, 
nebulisation, and early reporting of infections so that antibiotics therapy can be 
prescribed to manage the disease.  It was assumed for this study that these general 
requirements would be met by the CF patients and that the CF patients themselves would 
be interested in using a new product that may help their condition.  Apart form regular 
monitoring of the patients, at the CF clinics, there is no real way of measuring general 
compliance in these patients.  It was found in this study that compliance was half of the 
required dose in taking the straw and poor regarding the symptom diary.  Eating 
adequately involves frequent snacking during the day, taking additional food supplements 
and sometimes being fed enterally overnight.  Enzymes need to be taken with all meals 
and snacks.  Usually 1 to 4 enzyme capsules per meal/snack is the norm.  CF patients at 
the Addington Clinic take up to 10 capsules per meal.  Cystic Fibrosis patients use either 
singly, or a combination of, oral, inhaled or nebulized drugs to clear their lungs (Dodd & 
Webb 2000).   
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It has been demonstrated however that CF patients that attend CF clinics regularly have 
higher growth patterns and improved respiratory function (Anthony et al 1999).  Clinic 
attendance at the Addington & St Augustine’s Clinic involves taking the child out of 
school for the morning or day and their caregivers needing to take a day’s leave or the 
adult CF patient needing to take the day off work to attend the clinic.   
 
In general, the lack of compliance with using the straws meant that the therapeutic dose 
was seldom taken.  In addition only 50% of the symptom diaries contained information 
that could be used, compromising the quality of the results.  This in itself impacted on the 
rest of the study as it was hoped to show that supplementation with the probiotic would 
strengthen the immune system and decrease the number and duration of lung infections 




Because normal growth patterns vary by age and gender in order to compare weight and 
height changes in addition to using the weights and heights, anthropometric indices have 
been used in this study. 
 
The use of anthropometric indices is complicated by the fact that there are a number of 
different anthropometric indices for example %EWFH, BMI and Z scores and reference 
standards for example British Growth Standards (Lai et al 1999) and the National Centre 
for Health Statistics (NCHS).  Therefore in this study a range of anthropometric indices 
was calculated from the basic data of height, weight and age, to enable comparisons to 
the published data by Westwood & Saitowitz (1999).  Midarm circumference and Triceps 
skinfold thickness readings were only taken at the start and end of the study.  The end 
readings were then used to compare to the Cape Town data.  Other than this the MAC 
and TSF readings were not used as anthropometric indices in this study.  Due to the 






There was a significant average weight gain over the 12 month study period for all 
subjects.  The majority of the weight gained was during the period on placebo and not 
while on the probiotic which was disappointing.   
 
Over a similar period of time Guarino (2002) found a weight gain of 2.7% on placebo 
and 8.7% on the probiotic LGG.  In this Durban study the average weight gain on placebo 
was 4.4% and on the probiotic 2.5%.  The average age of Guarino’s subjects was 9 years.  
In comparison the weight gain for the Durban study for the ≤ 10 year old age group was 
5.5% on placebo and only 2.3% on probiotic.  In fact in this study the only age group to 
have gained more weight while on the probiotic was the 13 to 19.99 year olds and 
because of the small sample size this did not reach significance.  In addition those ≥ 20 
years actually lost weight while on probiotic although this did not reach significance.  
The difference in outcome between the studies may be because Guarino’s sample size 
was larger (n=30) resulting in greater statistical power.  He also used LGG as the 
probiotic which may be more effective than L. reuteri and his subjects may have been 
more compliant resulting in the full therapeutic dose of the probiotic being taken.  
Compliance in his study was not discussed  
 
Males (non significantly) and females (significantly) in all age groups gained weight 
across the 12 month study period.  Females gained more weight than males during the 
whole study period but this was not significant (p=0.377).  Although both males and 
females appeared to gain less weight while on probiotic this did not reach significance 
possibly due to the small sample size.  This contradicts Anthony et al (1999) who 
claimed that males do better than females.   
 
According to the WFA percentiles 50% of the subjects were under the 3rd percentile at 
the start and 42% at the end of the study8.  As the SA study done at Red Cross hospital by 
                                                 
8 End of study was used as this was the most recent data available 
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Hill et al (1988) found that 36% of their CF population were below the 3rd percentile for 
WFA, the extent of malnutrition experienced at the Durban clinics was higher in 
comparison.   
 
These results were confirmed by the WFA Z-scores and the %EWFA.  Although the 
clinic patients in the Durban study were gaining weight there was no increase in the WFA 
Z-scores or %EWFA therefore there was no improvement in nutritional status indicating 
that the prevalence of malnutrition was not decreasing in this clinic.    
 
In this study there were an equal number of males and females under the 3rd percentile 
WFA which again contradicts what Anthony et al (1999) found in their review article 
which stated that male CF patients generally do better than their female counterparts.   
 
The prevalence of malnutrition as defined by wasting (%WFH <75%)  was higher in the 
SA CF patients than in the Spanish CF patients as Molina et al (2001) claimed that only 
20% of the Spanish CF clinic suffered from frank malnutrition.  On what basis frank 
malnutrition was determined was not clear in his article9.  Westwood & Saitowitz (1999) 
found that the prevalence of malnutrition using %EWFH was related to age, in that the 
under 10 year olds were less malnourished than the older subjects.  This was not the case 
in this study as no one group seemed to be at a higher risk.   
 
It was hypothesized that it could be shown that patients on the probiotic would gain 
substantially more weight than those on the placebo and thus improve their nutritional 
status which in turn would have a positive effect on lung function and reduce the 
infection rate.  Due to the small numbers and poor compliance this could not be 
demonstrated.  
 
The hypothesis that there would be a greater weight gain, for the group as a whole, while 
taking the probiotic, would have to be rejected.   
                                                 




As to be expected height in the ≥ 20 year old age group did not increase over the study 
period as this group should have reached their growth potential.  For the group as a whole 
and in all age groups except the 10 to 12.99 year olds the increase in height was 
significant while the 10 to12.99 year olds experienced a non significant increase.  Again 
this contradicts Westwood & Saitowitz (1999) who claimed that over 10 year olds were 
the higher risk group for growth failure.   
 
For the group as a whole and in all age groups except the ≤ 9.99 year olds the increase in 
height was non significantly greater on the probiotic compared to the period on the 
placebo.  Guarino’s (2002) study did not appear to investigate the effect of probiotic on 
stature. 
 
Both the males and females increased significantly in height across the study.  All males 
except the 10 to12.99 years age group grew less on probiotic versus placebo although this 
was not significant.  In contrast all females non significantly increased in height more 
while on the probiotic except the 10 to12.99 age group.  In general the females appeared 
to be growing faster than and responding better to the probiotic than the males however 
this was not significant.  This contradicts Anthony et al (1999) who claimed that males 
tended to do better than females.   
 
In 1988 Hill et al reported that 24% of the CF patients at the Red Cross hospital were 
below the 3rd percentile for HFA and 11 years later in the same Red Cross CF clinics in 
1999 Westwood & Saitowitz published that 16.2% were below the 5th percentile for 
HFA.  It was suggested that this decrease in the prevalence of stunting could probably be 
attributed to the development of more effective enzymes, a more liberal high fat diet and 
other improved therapies (Westwood & Ireland 2000).  In 2005 however, 42% of the 
children in this study in the Durban Clinics were below the 5th percentile for HFA in spite 
of the advancement in treatment for the CF patient suggesting low level of compliance, as 
can be seen in this study, regarding treatment regimes, nutritional status has not improve 
 110
to the level that would be acceptable.  The KZN CF patients were experiencing a greater 
prevalence of stunting in comparison to the other SA clinics. 
 
Height for age Z-scores were poor and improved marginally for the group as a whole but 
similarly to the WFA Z-scores the change was non significant indicating that there was 
no alteration in nutritional status over the study period.  Although heights were increasing 
in both sexes over time the males were not growing as fast as their age dictated as can be 
seen by the non significant decrease in HFA Z-scores.  In contrast the females HFA Z-
scores increased non significantly indicating that their height was keeping pace with their 
age.  For all age groups for %EHFA were non significant and followed a similar pattern 
to the HFA Z-scores confirming that their nutritional status was poor and was not 
improving. 
 
The hypothesis that all subjects ≤ 19.99 year olds and younger, would improve in height 
more while taking the probiotic, would have to be rejected. 
 
5.3 COMPARISON OF ANTHROPOMETRIC STATUS OF CYSTIC FIBROSIS 
PATIENTS IN DURBAN AND CAPE TOWN 
 
Over half of the children in this study in the Durban clinics were underweight for their 
actual height compared to only one third of the Cape Town clinic.  In this study the 
Durban clinics had more subjects (39%) experiencing underweight and mild malnutrition 
as shown as %EWFH compared to CT (19%) confirming the weight and height findings 
that the patients are not optimally nourished and not in proportion for weight for height.  
The greater prevalence of malnutrition in the Durban clinics was confirmed by the higher 
number with MAC and TSF readings below the 5th percentiles.  In other words the 
children in the Durban clinics were leaner with low fat stores. 
 
The reasons for the differences between the Durban clinics and the Cape Town clinics 
were not investigated.  The number of patients and age groups of the KZN Durban study 
were comparable to the CT study published by Westwood & Saitowitz (1999). 
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As there was no significant difference in the height and weight of the subjects whether on 
or off probiotics it was felt that the readings at the end of the study would be more recent 
to compare to the Cape Town 1996 data.  
 
5.4 INCIDENCE AND DURATION OF LUNG INFECTIONS 
 
No significant association was found between taking probiotic or placebo and the 
incidence of lung infections.  Those taking probiotic in the first 6 months of the year 
showed a slight tendency to having less infections while on probiotic than placebo, while 
the group who took the placebo first had a similar number of lung infections whether on 
or off probiotic.   
 
The hypothesis that supplementation with L. reuteri would reduce the incidence of lung 
infections in CF patients would have to be rejected.   
 
More antibiotics were used in the first 6 month period compared to the second period and 
although the difference was significant it was regardless of whether they were on placebo 
or probiotic.  It is expected that CF get sicker in the winter months but as the study was 
over 12 months (with winter in the middle) this was not showing the seasonal difference.  
It would be of interest to see if the study was run for another 12 months whether a similar 
pattern of antibiotic use was shown. 
 
The use of antibiotics was not related to the use of either probiotic or placebo and there 
was no apparent effect of the probiotic on the number of infections as determined by the 
use of antibiotics.   
 
The hypothesis that supplementation with L. reuteri would shorten the duration of lung 





5.5 LUNG FUNCTION 
 
The results showed that while on probiotic the patients FEV1 and FVC readings improved 
although significance could not be reached probably due to the small sample size.  These 
are both direct objective measurements (Dodd & Webb 2000) so may more accurately 
reflect the effect of the probiotic rather than a subjective measurement such as days on 
antibiotics.  It is encouraging that there was an indication that the probiotic may be 
effective and if the correct dose was taken and better compliance achieved statistical 
significant may have be reached.   
 
The hypothesis was that CF patients taking L. reuteri would experience an improvement 
in lung function would have to be rejected.   
 
5.6       SPUTUM ANALYSIS 
 
In the Durban clinics 65.5% of the patients were infected with P. aeruginosa over the 12 
months.  These findings are in accordance with the South African data of Ventre et al 
(2000) who found more than two thirds of their patients at the Groote Schuur Clinic 
cultured P. aeruginosa and from overseas clinics where the infection rate ranged from 25 
to 85% (Hart & Winstanley 2002).   
 
The sputum score to measure bacteria was a direct objective measure to monitor the 
quantity of bacteria in the sputum for changes over time while on probiotic and while on 
placebo.  There was a non significant trend indicating that while on the probiotic the 
patients had marginally lower mean scores of bacteria in the sputum.  As P. aeruginosa 
has a negative impact on life expectancy these findings which showed a tendency 
towards the probiotic being effective are encouraging.   
 
The hypothesis that CF patients while taking L. reuteri would experience a decrease in 
the count of P. aeruginosa (dry and mucoid), S. aurens and B. cepacia in the sputum 
would have to be rejected. 
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5.7   SYMPTOMS 
 
The information from the symptom diaries should be viewed with suspicion.  Only eight 
(50%) were filled in most of which was incomplete and poorly filled in.  No significant 
difference was found in the incidence of coughing, wheezing, thrush, diarrhoea, 
constipation, vomiting and stomach ache whether on probiotic or on the placebo.  There 
was a significantly higher mean number of episodes of fever, runny nose, sore throat and 
ear ache while on probiotic according to the limited data extracted from the inaccurately 
completed symptom diaries.  Guarino (2002) found a reduction in stomach ache in 7 out 
of 9 subjects in his study.  It is possible that those who experienced more symptoms and 
were sicker tended to not complete their symptom diary on both occasions.  In addition 
the symptom diary is a subjective measure of compliance and has been reported by Dodd 
& Webb (2000) that when patients fill in a symptom diary they often overestimate their 
responses.  This would in fact tie up with the burden of treatment for CF in that they have 
huge time commitments needed for health care and filling in the symptom dairies 
increased that burden (Dodd & Webb 2000).  
 
The hypothesis that the mean episodes of symptoms would decrease while on the 
probiotic would have to be rejected. 
 
5.8  FOOD FREQUENCY QUESTIONNAIRE REGARDING PRE AND 
PROBIOTIC USE 
 
Generally just over 50% of the subjects used a food supplement from once or twice a 
week to three times a day.  Nutren Activ was consumed the most (25%) and contains the 
prebiotic fructoligosaccrides in the amount of 8.6g per 100g powder.  This amount of 
prebiotic once or twice week (n=1) to 3 times a day (n=1) was not considered to 
influence the study as the supplement was consistently taken prior and during the study.   
Nutren Activ is one of the feeds that are supplied to the CF patients at the clinics.   
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Yogurt was consumed by 81% of the subjects, 25% are brand specific.  Although 62.5% 
consumed yoghurt at least 1 to 7 times per week none were using a brand containing a 
known live probiotic.  Yogurt was not considered to have had any confounding affect in 
this study.  
 
No subjects were taking other supplements containing either pre or probiotics so the 
additional intake of either probiotics and prebiotics was unlikely to influence the study.   
 
5.9   SUMMARY 
 
The study set out to show that supplementation with a probiotic (L. reuteri) could 
stimulate the immune system, possibly reducing the incidence and shortening the 
duration of lung infections while maintaining or preventing deterioration in lung function.  
A reduction in the number of lung infections in turn would decrease both nutritional 
requirements and nutrient losses of the patients with CF while increasing food intake.  
This would hopefully improve nutritional status, which would enhance resistance to lung 
infections in turn interrupting the malnutrition/infection cycle.  It has been disappointing 
that because of a small sample size and poor compliance this could not be shown 
statistically.  However as a pilot study a lot of useful information was gained.  If the 
study is to be repeated it would be of interest to increase the dose and improve 
compliance of taking the probiotic, perhaps include other probiotics as a combination 
dose and maybe to extend the length of the study. 
 
5.10  STUDY LIMITATIONS 
 
Difficulties in carrying out this study included dealing with patients that already have a 
huge amount of treatment requirements to maintain their health and find it difficult to add 
yet another treatment option.  The extent of non compliance was unexpected.  After the 
payment was made to the subjects (at 6 months) their seemed to be a renewed awareness 
and more compliance was noted.  As it was the first time any study has been carried out 
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in this patient group there was not a lot of interest or enthusiasm with some of the 
medical staff to drive the process.  Study limitations have been listed below. 
 
5.10.1 The total number of CF patients attending both the CF clinics in KZN is relatively 
small and not all patients agreed to participate in the study.  Patient numbers were 
very small at the start of the study with a high drop off rate at the crossover. 
 
5.10.2 Poor compliance was a major problem.  Record keeping of the symptom diary 
was poor as was the use of the straws. 
 
5.10.3 The probiotic and placebo were not identical as the probiotic had a date stamp on 
the package but the placebo did not.  To overcome this, the person randomizing 
the probiotic/placebo put the straws into a brown paper packet so that the 
researcher was not aware which was being given out.  In addition once the straws 
were opened one could see the oil stain where the probiotics were located in the 
straw.  There was no oil stain on the placebo straw.  If the patients had seen both 
straws at the same time this difference would have been obvious.  This did not 
happen at the beginning of the trial as the straws were given out each six months.  
After 6 months once the second batch of straws was issued some of the patients 
noticed the difference.  This meant that after the first 6 months some of the 
patients had a good idea of whether they were taking placebo or probiotic.  At the 
end of the first 6 months a person not involved in the study was asked to count 
both the used and unused straws.  It was obvious from the totals that the count had 
been done incorrectly.  The researcher then had to recount the straws so breaking 
blinding.  At this stage no record was kept by the researcher as to which patient 
was taking which straw and she could not actually remember who was on active 
and who was on placebo.   
 
5.10.4 The study expected that all patients would be productive and be able to produce 
sputum samples at the start of the study.  This did not happen so sputum samples 
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were taken as close to the beginning, middle and end of the study when the patient 
was able to produce sputum. 
 
5.10.5 To standardize the sputum results permission was obtained from the state hospital 
to use their laboratory to process all the sputum.  The laboratory staff however 
were unwilling to process the samples from the private sector and claimed that 
they were not able to run the few additional sputum samples as they were short 
staffed.  Both the state and the private laboratory were therefore used.   
 
5.10.6 It was assumed that standard laboratory practice would take place.  After a few 
months the state laboratory changed the way that they processed the sputum 
results for the CF clinic without informing the researcher.  They claimed that the 
new technique would detect the number and type of bacteria in the sputum more 
accurately. 
 
5.10.7 It was anticipated that all patients would return to the clinic after the first 6 
months.  This did not happen.  Straws and symptom diaries were posted to 3 
patients that said that they could not make the clinic.  Straws and the symptoms 
diary were either posted back or collected at the next clinic they attended.  This 
meant that not all the anthropometric measurements were taken at the cross over. 
 
5.10.8 On two occasions an antibiotic was prescribed by the doctor but was not issued by 
the state pharmacy.  On another occasion a generic drug was given.  The collation 
sheets were poorly filled in by the doctors and some data had to be collected 
retrospectively from the files.  Patients who were prescribed antibiotics did not 
always complete the course. 
 
5.10.9 There was no time period allocated for a wash out between taking the probiotic 
and placebo or vise versa in the study.  The implication of this was that if there 
was a long term effect from the probiotic it would have had a carry on affect 
during the following six month period while the subjects were on the placebo.   
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5.10.10 Repeatability studies regarding anthropometric measurements between the two 
dieticians should have been carried out.   
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CHAPTER 6:  CONCLUSION AND RECOMMENDATIONS 
 
6.1    CONCLUSION 
 
Compliance in this study was poor resulting in the average patient taking only half or less 
of the effective therapeutic dose of probiotic.  Unlike the other studies, age did not seem 
to be a key determinant of compliance.  What appeared more important was the lack of 
immediate benefit, the lack of time due to the burden of treatment as well as the 
perception that the straws were not real medication.  If the study were to be repeated, 
using a more ‘medicinal’ approach such as probiotic tablets and offering immediate 
rewards for compliance, would be imperative.  
 
Although all the subjects across the study period showed a significant increase in actual 
body weight the non significant decrease in WFA percentiles and WFA Z scores 
confirmed that the amount of weight being gained was not sufficient and that their 
nutritional status was not improving.  As approximately half the clinic was wasted, 
malnutrition was a real issue in the Durban clinics.  A higher percentage of CF patients 
were wasted in comparison to their Cape Town counterparts indicating that the Durban 
clinics are not being as effective in their weight management.  Contrary to expectations 
the patients gained significantly more weight while on the placebo indicating that the 
probiotic may have unexplainably obstructed weight gain.  No age group appeared to be 
more susceptible to malnutrition and females certainly did not do worse than the males 
and may even have performed slightly better.   
 
Heights showed a similar trend to the weights in that overall their heights increased 
significantly across the study period.  However the slight non significant increase in HFA 
percentiles and HFA Z scores again demonstrated that their nutritional status was not 
altering.  Similarly to weight almost half the clinic were stunted confirming that 
malnutrition was a major challenge facing the clinic.  The prevalence of stunting was 
almost three times that reported by the Cape Town clinic indicating that the existence of 
chronic malnutrition was greater.  Again no particular age group was more susceptible 
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and females appeared to do non significantly better again contraindicating the belief that 
males are at a lower risk.  Although it was non significant their increase in height 
appeared to be greater while on the probiotic possibly the probiotic was promoting an 
increase in height at the cost of an increase on weight.  If taken at the correct therapeutic 
dose the increase in height might have reached significance.   
 
The %EWFH, the MAC and TSF readings emphasized the enormity of the problem 
facing the Durban clinics.  It has been well established therefore that malnutrition locally 
needs to be addressed and that Cape Town is managing the challenge more effectively 
probably because the clinic is better staffed and runs more frequently.   
 
Findings were encouraging for the effect of the probiotic on the CF lung as L. reuteri 
showed a non significant trend towards the improvement of lung function as objectively 
measured by FEV1 and FVC.  The subjective measurements of lung infection rate and 
duration showed a non significant trend in favour of the placebo.  However the objective 
measurement of sputum score again showed a non significant trend in favour of the 
probiotic.  These trends were very interesting as they were noticeable even though the 
majority of the study sample seldom reached the correct therapeutic dose the compliance 
was so poor.  A higher dose of probiotic might have been more appropriate due to the 
probability of the CF colonic microflora being seriously disturbed (Walters & Littlewood 
1998: Roy et al 1979)..   
 
The small sample size in combination with poor compliance lacked the power 
statistically.  With the available evidence therefore it was impossible to conclude with 
any confidence whether the use of the probiotic was beneficial, had no effect or was 
harmful.  
 
Alternative effective treatments to antibiotics are desperately needed in the treatment of 
CF patients.  The trends found in this pilot study deserve further investigation using a 
larger sample size recruited from other CF clinics in SA, a higher dose of probiotic with 
compliance being encouraged by offering financial or other incentives.  It is still hoped 
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that this could prove to be a novel, safe and affordable alternative to antibiotics for the 
CF patient.   
 
6.2    RECOMMENDATONS FOR DIETETIC PRACTICE 
 
Dieticians need to educate the CF patients on the dangers of malnutrition and put even 
more effort into encouraging both weight and height gain so that the prevalence of 
malnutrition decreases. 
 
Good anthropometric data needs to be regularly collected and monitored and shared with 
the other clinics in South Africa. 
 
As yet no recommendations can be made about the use of probiotics. 
 
6.3  RECOMMENDATIONS FOR IMPROVEMENT OF THE STUDY 
 
More subjects need to be included as numbers were too small on this study to reach 
significance.  A larger population group would make the statistics more powerful as 
shown in the study by Hatakka et al (2001). 
 
Stronger motivation is needed to keep the subjects compliant as this study group falls into 
the age range that is well documented as being non-compliant (Anthony et al 1999).  
Seventy-five rand each 6 months was issued on this study; if more money was available; 
subjects could be paid at each clinic visit for completed diaries and used straws.   
 
The therapeutic dose could be increased (a medium dose was used) and as the CF 
population is likely to have an abnormal colonic microflora (Walters & Littlewood 1998) 
a high dose may be more appropriate.  If the dose was increased taking into account a 




The form in which the probiotic is given could be changed from straws to chewable 
tablets for the older CF population.  This may improve compliance as they may feel as 
though they were taking a medication. 
 
6.4   IMPLICATIONS FOR FURTHER RESEARCH 
 
Further measurements of the anthropometric status of the CF patients would allow for 
continued monitoring of the malnutrition status of these patients. 
 
Although the study did not reach significance there was a positive trend to the probiotic 
playing a role in improving lung function and reducing the incidence of infections – it 
would therefore be important to investigate this further in a larger multi centre trial to 
determine whether the probiotic is an effective further treatment option. 
 
Probiotics given as a straw for the older patients was not perceived as medication and a 
capsule/tablet may have been a better option and could be used in a larger study.  
Probiotics as a single strain was used in this study to show an effect of that particular 
strain.  It has become popular to give 2 or more strains of probiotics and this would be of 
interest to see if a significant difference could be measured in this group of patients 
although one would not be able to attribute a change to any one probiotic.  However these 
supplements are now available in South Africa and would be available for the patients to 
consume after the study was completed.  As part of the KZN ethics requirements if a 
product is used in a study it has to be available for the patient to use after the study has 
been completed.  L reuteri was available for the patients to use after the study had ended.  
Prebiotics are becoming popular with some products containing both the pre and 
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APPENDIX A  LETTER OF INTRODUCTION 
 
Dear Clinic member 
 
As many of you know, I am the dietician who works in the CF clinic at St Augustine’s Hospital.  I am 
currently completing my master’s degree through the University of Kwazulu-Natal.  I have decided to do a 
clinical trial exploring the potential of a natural product to both reduce the incidence and duration of lung 
infections in CF.   
 
You could help contribute to the knowledge of cystic fibrosis by participating in a 12 month trial that I 
would like to conduct on all CF members of both clinics in Kwazulu-Natal.  If the trial is successful the 
study would than expand to include all the other CF clinics in South Africa. 
 
I intend to measure the effect of a probiotic, Lactobacillus reuteri, on both lung function and the number of 
lung infections in CF.  To make the results of my study recognizable both locally and internationally it is 
very important to have an active and a non active treatment group.  Both groups will receive identical 
looking product and neither myself, the rest of the medical team or you will know which group you are in.  
Each participant will receive active product for 6 months and placebo for six months.  At the end of the trial 
you will be told which group you were in and the results of the study.  If successful, the probiotic is 
available locally if you choose to continue treatment. 
 
If you agree to be part of the study I will need you to take the probiotic/placebo daily for 12 months and 
keep a record of the number and duration of any lung infections that you experience during this period.  
Most of the information that I need is routinely done such as sputum samples, height, weight and lung 
function tests.  In addition at the start and end of the study I will measure your mid arm circumference and 
triceps skin fold thickness and you will be asked a short questionnaire.  There may be an extra clinic visit at 
both the start, in the middle, and at the end of the study if you were not due to attend the clinic in that 
month.  You will be offered compensation for the extra petrol costs and a small gratuity for taking part in 
the trial.  There will be no cost to you to participate in the study. 
 
Lactobacillus reuteri has GRAS status in America, which means that it is Generally Recognized As Safe so 
there is no foreseeable risk to you as a consequence of participating in my study.   
 
You will be free to withdraw from the study at any time without prejudicing any treatment that is required 
for existing or future medical conditions.   
 
If you have any questions regarding the trial please do not hesitate to contact any of the CF doctors, 
physiotherapist or myself.  We will be available at the next clinic to answer questions.  At the start of the 
trial the trial will be explained to you in detail before the consent form is collected from you.   
 
Ethics approval has been received from the University of Kwazulu-Natal, Nelson Mandela School of 
Medicine.  If you have any queries or concerns regarding the ethics of this study you may contact the 
Medical Research Administration, telephone number 031 2604604, fax 031 2604410 or email 
ethicsmed@ukzn.ac.za.  
 


















APPENDIX B  DOCTORS COLLATION SHEET 
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APPENDIX D 1  INFORMED CONSENT ADULTS  
 
I hereby confirm that I have been informed by the research assistant about the nature, 
conduct, benefits and risks of the clinical study reference number Ref.:E048/04.    
 
Ethics approval has been received from the University of Kwazulu-Natal, Nelson 
Mandela School of Medicine.  If you have any queries or concerns regarding the ethics of 
this study or your rights as a research subject, you may contact the Medical Research 
Administration, telephone number 031 2604604, fax 031 2604410 or email 
ethicsmed@ukzn.ac.za.  
 
 I have also received, read and understood the written information (letter of 
introduction and informed consent form) regarding the clinical study. 
 
 I am aware that I am agreeing to participate in a research study where a treatment 
is under investigation, which may not personally benefit me. 
 
 I am aware that the results of the study, including personal details will be 
anonymously processed into a study report and will remain confidential. 
 
 I am willing to allow the Ethics committee full access to my medical records if it 
becomes necessary to verify study procedure and/or data. 
 
 I am willing to allow the medical team (doctor, dietician and physiotherapist) full 
access to my medical records during and after the trial. 
 
 I understand that I may, at any stage, without prejudice, withdraw my consent and 
participation in the study. 
 
 I understand I may contact Mandy Read at 031 2011154 any time if I have 
questions about the research. 
 
 I declare myself prepared to participate in the study and have informed my doctor. 
 
 I understand if I agree to participate, I will be given a signed copy of this 
document and the participant information letter, which is a written summary of 
the research. 
 
 The research study, including the above information, has been described to me 
orally.  I understand what my involvement in the study means and I voluntarily 





Printed Name    Signature   Date 
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APPENDIX D 2 INFORMED ASSENT FOR MINORS (under 18 years): 
 
I hereby confirm that I have been informed by the research assistant about the nature, 
conduct, benefits and risks of the clinical study reference number (Ref.: E048/04).      
 
Ethics approval has been received from the University of Kwazulu-Natal, Nelson 
Mandela School of Medicine.  If you have any queries or concerns regarding the ethics of 
this study or the rights of your child or ward as a research subject, you may contact the 
Medical Research Administration, telephone number 031 2604604, fax 031 2604410 or 
email ethicsmed@ukzn.ac.za.  
 I have also received, read and understood the written information (letter of 
introduction and informed consent form) and had an opportunity to discuss this 
study with the research assistant at the CF clinic. 
 
 I am aware that I am agreeing for my child or ward to participate in a research 
study where a treatment is under investigation, which may not personally benefit 
my child or ward or me. 
 
 I am aware that the results of the study, including personal details will be 
anonymously processed into a study report and will remain confidential. 
 
 I am willing to allow the Ethics committee full access to my child or ward’s 
medical records if it becomes necessary to verify study procedure and/or data. 
 
 I am willing to allow the medical team (doctor, dietician and physiotherapist) full 
access to my child or wards medical records during and after the trial. 
 
 I understand that I may, at any stage, without prejudice, withdraw my consent for 
my child or ward to participate in the study. 
 
 I declare myself prepared for my child or ward to participate in the study and have 
informed the CF doctor. 
 
 I understand if I agree to give consent as the parent/guardian for my child or ward 
to take part in the trial I will be given a signed copy of this document and the 
participant information letter, which is a written summary of the research.  
 
 The research study, including the above information, has been described to me 
orally.  I understand what the involvement of my child or ward in the study means 
and I voluntarily agree to his/her participation. 
PARENT/GUARDIAN: 
 
Printed Name    Signature   Date 
 
On behalf of the PATIENT (minor): 
Printed Name 
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APPENDIX E FOOD FREQUENCY QUESTIONNAIRE REGARDING PRE 
AND PROBIOTIC USE 
 
Name:  Date of birth  
Male  Female  
 
Are you currently taking any of the following food supplements? Yes  No 
If yes which of the following? 
Build up   Sustagen T   
Ensure   Complan   
Nutren   Herbalife   
Sustagen   Other   
Other  
Other  
If yes, how often do you have a glass?  
Once a day   2 x day   
 3 x day   4 x day   
1 or 2 x week    1 or 2 x month   
Other amount       
       
       
Do you make it up according to 
directions?  Yes / No 
If not how do you 
make it up?    
    
Do you eat yogurt?  Yes No 
If yes, how often?  
Once a day   2 x day   
 3 x day   4 x day   
1 or 2 x week    1 or 2 x month   
Other amount       
       
       
Any specific brand?   Yes No 
If yes, which brand/brands 
 
   
 
Do you take any vitamin supplements?   Yes No 
If yes, which brand/make?    
How often do you take them?    
Once a day 2 x day 3 x day 1 or 2 x week 





How many do you take at a time?    
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Do you take any mineral supplements?   Yes No 
If yes, which brand/make?    
   
How often do you take them?    
Once a day 2 x day 3 x day 1 or 2 x week 





How many do you take at a time?  
       
Do you take any vitamin & mineral 
supplements?  Yes No 
If yes, which brand/make?    
      
How often do you take one?      
Once a day 2 x day 3 x day 1 or 2 x week 





How many do you take at one time?  
    
Do you take any other food/herbal/alternative supplements?   Yes No 
Garlic & parsley   n-3 fatty acids   
Interflora   BioPro    
       
Other:  
Other:  
 If Yes which brand/make? 
   
How many do you take at a time?  
If yes, how often do you take them?       
Once a day 2 x day 3 x day 1 or 2 x week 








When you take an antibiotic do you take any other supplements? Yes No 
Eg Interflora/CoBiotic?Nutriflora?Kiddieflora?BioPro  
 
 
If you take a supplement, how many do you take at a time?  
If yes, how often?    
Once a day  2 x day  3 x day  1 or 2 x week 
 1 or 2 x month 
Occasionally when 
you remember     
Other 
If any new products are started during this 6 months please inform the dietician    
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This CF patient is currently taking part in a 12-month clinical trial investigating the efficacy of a 
probiotic on the occurrence and duration of lung infections in CF.   
 
While they may need your assistance with a lung infections during this time please would you be 
so kind as to fill in the attached form to record the type and duration of treatment and fax it back 
to the phone number attached. 
 
Due to the nature of this trial please could you refrain from scripting any probiotics or prebiotics 
including interflora during this time period.  Should you have any queries regarding the scope of 
these please contact me at (031) 2011154.   
 
















Pseudomonas  Staphylococcus  Haemophilus  




















 Dose  
Other 
 




































































APPENDIX L DETAILED INFORMATION FOR MIDARM 
CIRCUMFERENCE AND TRICEPS SKINFOLD 
THICKNESS READINGS 
 
The mean MAC at the start of the study was 22.6 cm and 23.3 cm at the end of the study 



























































All age groups improved their MAC readings for the study period except the ≥ 20 year 
old who’s MAC decreased. All were non significant findings except for the 13 to 19.99 
year old group whose MAC increased significantly (p=0.008).   
 
The mean MAC for males was 23.5 cm at the start and 23.9 cm at the end of the study 
(Table 36).  This difference of 0.4 cm was not significant (p=0.408).  The males MAC 
improved non-significantly for all but the ≥ 20 year olds whose MAC decreased over the 










































































The mean MAC for the female group as a whole was 21.4cm at the start of the study and 
improved to 22.6cm by the end of the study period showing a 1.2cm increase which was 
a significant finding of p=0.015 (Table 37).  All other female age groups also improved 
their MAC readings non significantly over the study period.   
 
When comparing the MAC for males and females there was a non significant difference 
























































The mean TSF for the whole group at the start of the study was 8.44 mm and 8.06 mm at 
the end of the study (Table 35).  This was a non significant decrease of 0.38 mm 
(p=0.405).  Only 4 (all ≤ 13 years) improved their TSF readings for the study period.  
Twelve patients (all 14 years to ≥ 20 years) decreased their TSF over the study period but 
these were non significant findings.   
 
For the male group as a whole there was a significant (p=0.047) decrease in the TSF 
readings (Table 36) from the start to the end of the study.  The only male group to 
improve was the ≤ 9.99 year olds, while all other age groups decreased their TSF over the 
study period.  All the females increased their TSF over the study period with the 
exception of the 27 year old female who’s TSF decreased.  This was non significant 
(p=0.971) (Table 37).  When comparing the TSF for males and females there was a 
significant difference between them at the start (p=0.011) and the end of the study 
(p=0.005).   
 
 
